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Degradable polymers have gained increasing interest in the molecular probe and 
nanomedicine research, which avoid safety concerns of non-degradable materials after long-term 
accumulation in the human body.  This dissertation focuses on the rational design and synthesis 
of biocompatible polymers, based on polyphosphoesters (PPEs) and poly(glucose carbonate)s 
(PGCs), which are capable of serving as non-immunotoxic antifouling coatings for molecular 
nanoprobes to accurately image tumors, or formulating well-defined functional nanocarriers for 
therapeutics to effectively treat osteosarcoma lung metastasis or bacterial infections.     
In the first study, zwitterionic PPEs (zPPEs) were developed as coating materials for gold 
nanoparticles (AuNPs), which showed minimal immunotoxicity and advanced antifouling 
property.  The PPE was synthesized by a rapid organocatalyzed ring-opening polymerization 
(ROP), followed by post-polymerization modification via the thiol-yne click reaction to afford 
the zPPEs.  Degradability of the zPPEs was investigated in nanopure water (pH 5-6), which 
proceeded to ca. 75% after 2 d, and ca. 90% by 7 d, consistent with the degradation profiles of 
the zPPE-coated AuNPs.  Compared to their counterparts coated with poly(ethylene glycol) 
(PEG), the zPPE-coated AuNPs showed similar sizes and low immunotoxicity.  Moreover, 
significantly reduced cytokine adsorption was observed for the zPPE-coated nanoparticles.  The 
degradability, biocompatibility and advanced antifouling property demonstrate the zPPE to be a 
potential PEG alternative coating material for molecular nanoprobes.   
To circumvent potential drawbacks of our previous PPE system, namely the production 
of ethylene glycol and phosphoric acid upon hydrolytic degradation, sugar-derived PGC-based 




nanocarriers for anticancer drugs to treat osteosarcoma (OS) lung metastases.  Two PGC-based 
block polymers and one dimeric paclitaxel pro-drug (diPTX) were designed to be co-assembled 
into nanoparticles with tunable sizes and surface charges as a redox-responsive nanomedicine.  
The formulation showed sustained release of the PTX free drug in the presence of glutathione, a 
reducing agent existing at high levels in tumor tissues, thereby resulting in significant selectivity 
in killing cancer cells over healthy cells.  Both in vitro and in vivo anticancer studies confirmed 
the capability of the formulation to penetrate tumor tissues and inhibit tumor cell growth, 
indicating its promise for the treatment of OS lung metastases.   
In the third study, a novel PPE-based triblock polymer was designed and synthesized, 
which avoided the hydrolytic degradation product ethylene glycol, and allowed for facile 
construction of silver-loaded Janus nanoparticles as a potential antimicrobial.  The polymer was 
synthesized by a one-pot sequential organocatalyzed ROP of a cyclic phosphotriester and L-
lactide with PEG as the macroinitiator, followed by post-polymerization modification via the 
thiol-ene click reaction.  Biocompatibility of the polymer was confirmed by cytotoxicity assays.  
The well-defined silver-loaded Janus nanoparticles were then prepared by simply irradiating the 
mixture of the PPE-based polymer and silver acetate solutions under UV for a few minutes.  
Within 2 h dialysis against nanopure water, ca. 50% of silver was released from the Janus 
nanoparticles, with the remaining silver released in a much slower manner over 40 h, which could 
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CHAPTER I  
INTRODUCTION 
Nanoparticles have been extensively investigated for biomedical applications in disease 
diagnosis and therapeutic delivery, due to their unique characteristics associated with the 
nanoscale sizes, such as high surface-to-volume ratios, tunable nanostructures, and optimal 
physical and chemical properties.1-5  By labeling with imaging agents, such as near-infrared 
(NIR) dyes and radioactive isotopes, nanoparticles are capable of serving as molecular 
nanoprobes for accurate diagnosis after they are accumulated in the diseased sites of the human 
body.  Nanomedicine has also shown great potential for the treatment of a wide range of diseases.  
Compared to free drugs, nanocarriers can offer many advantages, including protection of the drug 
from degradation, prevention of the drug from premature interactions with the biomolecules, and 
improvement of the pharmacokinetic and tissue distribution profiles of the drug.  One of the 
advantages of molecular nanoprobes and nanomedicine is the enhanced permeability and 
retention (EPR) effect, which is an important benefit of nanoscopic agents in cancer diagnosis 
and therapy.  The EPR effect results from the extravasation of nanoparticles through tumor blood 
vessels into the tumor interstitial space due to the high permeability of the tumor vasculature.  
The nanoparticles will then remain and accumulate in the tumor because of the compromised 
lymphatic filtration.  In comparison to low-molar-mass agents, which are not retained in the 
tumor because of their diffusion back to circulation, nanoparticles show selectivity for tumors 
over normal organs and tissues, thereby leading to increased efficacy and reduced side effects.  
In addition to passive targeting, active targeting of molecular nanoprobes and nanomedicine can 




biomarkers on the diseased tissue cells or pathogens, which is able to increase treatment efficacy 
and minimize the off-target effects in the non-targeted organs.  Yet, recently, the biomedical 
research of nanoparticles has drawn a few concerns, including high costs arising from the 
sophisticated structures, relatively low outcome in the efficacy improvement, and possible batch-
to-batch variations.6  Therefore, development of nanoplatforms with enhanced chemical and 
physical properties from facile and well-controlled approaches is highly desirable.   
Rapid construction of nanoparticles can be realized through the assembly of amphiphilic 
polymers, with their structures finely designed and tuned to introduce versatile functionalities 
and achieve desirable properties.7  Moreover, polymers can be also be utilized as the coating 
materials to stabilize inorganic nanostructures, combining the advantages of both the organic 
polymeric coatings and inorganic metal cores to formulate advanced hybrid materials.  
Degradable polymers, such as polyesters,8 polypeptides,9 polyphosphoesters (PPEs),10-11 and 
polycarbonates,12 have gained increasing interest in biomedical applications, which are capable 
of avoiding safety concerns of non-degradable materials after long-term accumulation in the 
human body.  PPEs are biocompatible, degradable and structurally similar to biomacromolecules, 
which have been applied for rapid construction of diverse functional nanostructures as gene and 
drug delivery systems.  Our group has developed a series of PPEs to formulate nanoparticles for 
drug delivery applications, with their degradability, biocompatibility, versatile functionality, and 
facile and controlled synthetic approaches.13-19  Rational design and optimization of the chemical 
structures of PPEs have been conducted, which are further investigated on their applications in 
tumor imaging and drug delivery.  Recently, functional glucose-derived PGCs are also employed 
by our group to construct nanostructures with tunable sizes, surface charges, and morphologies, 




ethanol.20  The PGC-derived nanostructures as nanocarriers were expected to circumvent 
potential drawbacks of our previous PPE system, namely the production of ethylene glycol and 
phosphoric acid upon hydrolytic degradation, while maintaining the advantages.  Ring-opening 
polymerization (ROP) is a facile, highly repeatable, and well-controlled technique to obtain these 
polymers.  Organocatalysts have been reported by many groups to be able to promote ROPs of 
cyclic monomers, including esters, phosphoesters, and carbonates, which will eliminate the use 
of traditional environmentally sensitive metallic catalysts and leave no residual metal 
contaminants.  The organic catalysts, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), and 1,5,7-
triazabicyclo[4.4.0]dec-5-ene (TBD), have been applied for the preparation of polymers in this 
dissertation.  Click chemistry is a class of highly selective and bioorthogonal reactions that yields 
no side products under a variety of mild reaction conditions.  The click-type reactions have been 
utilized to conveniently install specific functionalities and charges to the polymers under 
investigation.   
Despite the rapid development of modern pharmaceutical research, cancers and bacterial 
infections remain great threats to human lives globally.21  Cancer is reported by the World Health 
Organization (WHO) to be the second leading cause of deaths worldwide, resulting in ca. 9.6 
million deaths in 2018.22  It is estimated that 1 in 6 deaths globally is due to cancer.  Bacterial 
infection is another cause for significant morbidity or mortality if not properly treated.23  
Antimicrobial resistance developed by bacteria is one of the key factors for the treatment failures 
and increased severity of infections.  According to the Centers for Disease Control and 
Prevention (CDC) of the United States, more than two million patients are infected with 
antibiotic-resistant bacteria each year, which directly results in at least 23000 deaths nationwide, 




of novel therapeutics and strategies for the diagnosis and treatment of cancers and bacterial 
infections are of critical need.  One of our target diseases is osteosarcoma (OS), which is the most 
common primary cancer of bone in children and adolescents aged 10-20 years and the third most 
common cancer overall in adolescents, with no proven etiology and a high fatality rate (70% 
survival at 5 years for non-metastatic patients, and less than 30% for those presenting with 
metastasis).26-28  The predominant site of metastasis is the lung, followed by other bones.  Once 
micrometastases grow into recurrent, overt disease, tumors are often resistant to conventional 
chemotherapy, and unresectible recurrent disease is fatal.  Therefore, there is a pressing need to 
develop effective approaches to the prevention and treatment of the metastatic disease.  Another 
target disease under our investigation for treatment is the pulmonary infection associated with 
the antibiotic-resistant bacteria, such as Pseudomonas aeruginosa.  Lower respiratory infections 
are reported to be the most deadly communicable disease, leading to 3.0 million deaths in the 
world in 2016.23  The increasingly serious health threat from pulmonary infections associated 
with the continually evolving resistant pathogens has made imperative the development of novel 
antimicrobials and innovative delivery strategies.   
This dissertation will describe the rational design, synthesis and biomedical applications 
of polymers comprised of the degradable and biocompatible PPEs or PGCs.  Well-defined 
nanoparticles were fabricated from the polymers with their unique chemical and physical 
properties to serve as molecular nanoprobes for tumor imaging, or to deliver the anticancer drug 
PTX for cancer therapy, and silver-based antimicrobials for treatment of bacterial infections.  In 
Chapter II, a zwitterionic PPE (zPPE), specifically L-cysteine-functionalized poly(but-3-yn-1-
yloxy)-2-oxo-1,3,2-dioxaphospholane (zPBYP), has been developed as a poly(ethylene glycol) 




investigated metal nanoparticulate platform towards molecular imaging, photothermal therapy, 
and drug delivery applications.  31P NMR studies in D2O revealed ca. 20% hydrolysis of the 
phosphoester moieties of the repeat units had occurred during the work-up and purification by 
aqueous dialysis at pH 3 over ca. 1 d, as observed by the 31P signal of the phosphotriesters 
resonating at ca. -0.5 to -1.7 shifting downfield to ca. 1.1 to -0.4 ppm, attributed to transformation 
to phosphates.  Further hydrolysis of side chain and backbone units proceeded to an extent of ca. 
75% over the next 2 d in nanopure water (pH 5-6).  The NMR degradation results were consistent 
with the broadening and red shift of the surface plasmon resonance (SPR) observed by UV-Vis 
spectroscopy of the zPPE-coated AuNPs in water over time.  All AuNP formulations in this 
study, including those with citrate, PEG, and zPPE coatings, exhibited negligible 
immunotoxicity, as determined by cytokine overexpression in the presence of the nanostructures 
relative to those in cell culture medium.  Notably, the zPPE-coated AuNPs displayed superior 
antifouling properties, as assessed by the extent of cytokine adsorption, relative to both the 
PEGylated and citrate-coated AuNPs.  Although nanomedicines have been pursued for nearly 
twenty years, fundamental chemical strategies that seek to optimize both the drug and drug carrier 
together in a concerted effort remain uncommon, yet may be powerful.  In Chapter III, two block 
polymers and one dimeric pro-drug molecule were designed to be co-assembled into degradable, 
functional nanocarriers, where the chemistry of each component was defined to accomplish 
important tasks.  The result is a PEG-protected redox-responsive dimeric PTX (diPTX)-loaded 
cationic poly(D-glucose carbonate) micelle (diPTX@CPGC).  These nanostructures showed 
tunable sizes and surface charges and displayed controlled PTX drug release profiles in the 
presence of reducing agents, such as glutathione (GSH) and dithiothreitol (DTT), thereby 
resulting in significant selectivity for killing cancer cells over healthy cells.  Compared to free 
6 
PTX and diPTX, diPTX@CPGC exhibited improved tumor penetration and significant inhibition 
of tumor cell growth towards osteosarcoma (OS) lung metastases with minimal side effects both 
in vitro and in vivo.  In Chapter IV, a facile, rapid and conveniently-controlled approach to 
synthesize silver-loaded PPE-based Janus nanoparticles is developed.  A biocompatible triblock 
polymer, methoxy poly(ethylene glycol)-block-poly(2-ethoxy-4-vinyl-1,3,2-dioxaphospholane-
2-oxide)-block-poly(L-lactide) (mPEG-b-PE4VP-b-PLLA), was designed and synthesized by a 
one-pot ring-opening polymerization (ROP), followed by post-polymerization modification via 
a thiol-ene click reaction.  Self-assembly was investigated by directly dissolving the polymer into 
the MOPS buffer (pH = 7.4) to form anionic nanoparticles, which showed reduced cytotoxicity 
compared to previously reported PPEs.  The solutions of the anionic PPE-based nanoparticles 
and silver acetate (10 wt% Ag relative to the polymer) were allowed to stir and irradiated under 
UV (365 nm, 500 µJ/cm2).  Rapid formation of snowman-like Janus nanoparticles was confirmed 
by TEM and AFM images, with the reaction progress controllable by the irradiation time.  Within 
2 h dialysis against nanopure water, ca. 50% of silver was released from the Janus nanoparticles, 
with the remaining silver released in a much slower manner over 40 h, which could be beneficial 




CHAPTER II  
FUNCTIONAL, DEGRADABLE ZWITTERIONIC POLYPHOSPHOESTERS AS 
BIOCOMPATIBLE COATING MATERIALS FOR METAL NANOSTRUCTURES 
 
2.1 Introduction  
Metal and metal oxide (MO) nanoparticles (NPs) have been extensively explored for 
imaging, photothermal therapeutic, and drug delivery applications, due to their tunable 
photophysical properties, accessed by feasible syntheses that allow for control over their sizes 
and morphologies.29-30  To improve the aqueous stability and decrease the undesirable non-
specific protein adsorption (opsonization) of NPs, both of which are critical factors that affect in 
vivo fate, various hydrophilic natural and synthetic polymers have been developed and used as 
coating materials to construct polymer-metal/MO hybrid nanostructures through ligand 
displacement reactions.31-32  Moreover, the incorporation of polymer components also provides 
facile pathways for introducing cell targeting and/or multimodule imaging functionalities, 
enabling responsive properties, and enhancing the loading and release performance of NP 
delivery platforms  
Poly(ethylene glycol) (PEG) represents the “gold standard” polymeric coating material 
for polymer-metal hybrid nanostructures.33  It has been well-established that the PEG can 
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improve NP water solubility, inhibit colloidal aggregation, and reduce the NP opsonization under 
physiological conditions.34-35  However, recent research has indicated that PEGylated 
biomaterials could lose stealth functions and undergo accelerated blood clearance by 
mononuclear phagocyte system (MPS) organs after repeated doses, due to the production of anti-
PEG antibodies by the immune system.36-38  Additionally, conventional telechelic PEGs are non-
biodegradable and lack feasibility for introduction of multiple functional moieties.  Therefore, 
the development of alternative coating materials that provide comparable stabilization and stealth 
capabilities, evade recognition by the immune system, offer degradability, and impart 
functionalizable groups is highly desirable for nanoscopic polymer-metal hybrid biomaterials.   
Zwitterionic antifouling polymers, e.g., poly(carboxybetaine) (PCB),39 
poly(phosphorylcholine)40-41 and poly(sulfobetaine),42 are potential alternatives to PEG-based 
coatings, as they are highly resistant to nonspecific protein adsorption.43  However, our previous 
results showed that, despite the comparable in vivo stealth properties of PCB to PEG, in certain 
circumstances, PCB-coated polymeric NPs could exhibit elevated immunotoxicity, in 
comparison with their PEGylated analogues.44  Biodegradable polymers, such as polyesters,8  
polyphosphoesters (PPEs)10-11, 45 and poly(glucose carbonate)s (PGCs),46 have been studied as 
promising materials for biomedical applications, which reduce the potential for long-term 
accumulation and associated adverse effects.  Our group has developed degradable zwitterionic 
polymers, including  PPE,19 and PGC,20, 47 to address the immunotoxicity issues.48  Interestingly, 
polymeric NPs with L-cysteine-functionalized, degradable zwitterionic PPE (zPPE)-based 
shells16, 18-19 exhibited noticeably-decreased immunotoxicities, particularly after shell 
crosslinking.  Based upon these results, we hypothesized that the utilization of zPPEs as coating 




maintaining the favorable antifouling properties of PCB.49  Moreover, the cysteine-derived 
carboxylic acids and amines in the zPPE corona provide opportunities for crosslinking to enhance 
the rigidity and stability of the composite nanomaterials.   
In this report, a degradable zPPE, namely L-cysteine-functionalized poly(but-3-yn-1-
yloxy)-2-oxo-1,3,2-dioxaphospholane (zPBYP), was synthesized and explored as a PEG-
alternative coating material for gold NPs (AuNPs), the most extensively-investigated metal 
nanoparticulate platform towards molecular imaging, photothermal therapy, and drug delivery 
applications.50  Although the utilized zPBYP experienced minor amounts of degradation during 
the purification process, its capabilities of stabilizing AuNPs, avoiding long-term accumulation 
by further degradation, realizing minimal immunotoxicity, and decreasing cytokine adsorption 
relative to AuNPs coated with PEG and citrate, were demonstrated.  Our investigation also 
supported that the ultrasmall gold nanoclusters (AuNPs with hydrodynamic diameter < 10 nm) 
could be potential platforms for in vivo diagnostic and theranostic applications.   
2.2 Materials and methods 
2.2.1 Materials 
Dichloromethane (DCM) and N,N-dimethylformamide (DMF) were purified by a solvent 
purification system (J. C. Meyer Solvent Systems, Inc., Laguna Beach, CA).  Nanopure water 
(18 MΩ·cm) was acquired from a Milli-Q water filtration system (Millipore Co.).  Phosphate-
buffered saline (PBS) was purchased as a 10× solution from VWR and diluted to a concentration 
of 1× in nanopure water.  Thioctic acid-terminated PEG (TA-PEG-OMe, 750 Da) was purchased 




Sigma-Aldrich, Co. (St. Louis, MO) unless otherwise noted.  Dialysis membrane tubing with a 
molar mass cut-off (MWCO) of 3.5 kDa was purchased from Spectrum Laboratories, Inc. 
(Rancho Dominguez, CA) and soaked for 5 min in nanopure water at room temperature (rt) 
before use.   
2.2.2 Instrumentation 
1H NMR, 13C NMR and 31P NMR spectra were acquired on a Varian Inova 500 
spectrometer interfaced to a UNIX computer using VnmrJ software.  Chemical shifts in the 1H 
NMR and 13C NMR spectra were referenced to the residual solvent resonance signals, while 
those in the 31P NMR spectra were referenced to an external standard, 85% H3PO4 in D2O.  FT-
IR spectra were recorded on an IR Prestige 21 system (Shimadzu Corp., Japan), equipped with 
an attenuated total reflectance (ATR) accessory, and analyzed using IRsolution v. 1.40 software.  
Ultraviolet-visible (UV-Vis) spectroscopy measurements were performed on a Shimadzu UV-
2550 spectrophotometer.   
Size exclusion chromatography (SEC) eluting with DMF was conducted on a Waters 
Chromatography, Inc. (Milford, MA) system equipped with an isocratic pump (model 1515), a 
differential refractometer (model 2414), and a four-column set, including a 5 μm Guard column 
(50 × 7.5 mm), a Styragel HR 4 5 μm DMF column (300 × 7.5 mm), a Styragel HR 4E 5 μm 
DMF column (300 × 7.5 mm), and a Styragel HR 2 5 μm DMF column (300 × 7.5 mm).  The 
system was equilibrated at 50 °C in pre-filtered DMF containing 0.05 M LiBr with the flow rate 
set to 1.00 mL/min.  Data collection and analysis were performed with Discovery32 v. 1.039.000 
software (Precesion Detectors, Inc.).  Molecular weights were determined relative to polystyrene 




solutions were prepared at a concentration of ca. 3 mg/mL with 0.05 vol% toluene added as a 
flow marker, and an injection volume of 200 μL was used. 
Thermogravimetric analysis (TGA) was performed under Ar atmosphere using a Mettler-
Toledo model TGA/DSC 1 with a heating rate of 10 °C/min.  Glass transitions (Tg) were 
measured by differential scanning calorimetry (DSC) on a Mettler-Toledo DSC822® (Mettler-
Toledo, Inc., Columbus, OH) under N2(g).  DSC measurements were performed with a heating 
rate of 10 °C/min and analyzed using Mettler-Toledo Stare v. 10.00 software.  The Tg was taken 
as the midpoint of the inflection tangent of the second heating scan.   
Electrospray ionization mass spectrometry (ESI-MS) experiments were performed using 
a Thermo Scientific LCQ-DECA instrument.  The sample was directly infused at a flow rate of 
6 µL/min.  The spray voltage was set to -4.5 kV, and the sheath gas and auxiliary gas flow rates 
were set to 50 and 10 arbitrary units, respectively.  The transfer capillary temperature was held 
at 250 °C.  Xcalibur 2.0 software was used for data acquisition and processing. 
Inductively coupled plasma-mass spectrometry (ICP-MS) was performed on a 
PerkinElmer SCIEX ICP mass spectrometer ELAN DRC II, equipped with a high-speed 
quadrupole, dynamic reaction cell (DRC) and axial field technology (AFT) to eliminate 
polyatomic interference, using 1% HNO3 as the matrix and rhodium as the internal standard.  The 
amount of Au in each sample was determined by ICP-MS after dilution with 1% HNO3.   
High-resolution scanning transmission electron microscopy (STEM) was conducted on a 
FEI Tecnai G2 F20 FE-TEM coupled with energy-dispersive X-rays (EDX), operating at a 
voltage of 200 kV and equipped with a Gatan CCD camera.  Samples for TEM were prepared as 




copper grid, and after 1 min, excess solution was quickly wicked away by a piece of filter paper, 
and the samples were left to dry under ambient conditions overnight.   
Dynamic light scattering (DLS) measurements were conducted using a Delsa Nano C 
instrument from Beckman Coulter, Inc. (Fullerton, CA) equipped with a laser diode operating at 
633 nm.  Scattered light from 0.5 mL samples in a disposable polystyrene cell (0.9 mL capacity) 
was detected at 165° and averaged over 70 accumulations.  The photomultiplier aperture and 
attenuator were adjusted automatically to obtain a photon count rate of ca. 10 kcps.  The particle 
size distribution and distribution averages (i.e., the intensity-, volume- and number-average 
hydrodynamic diameters) were calculated using CONTIN particle size distribution analysis 
routines in Delsa Nano 2.31 software.  All measurements were repeated 10 times. 
Atomic force microscopy (AFM) was performed using a Multimode 8 system (Bruker) 
in PeakForce® tapping mode using a ScanAsyst-Air Silicon Nitride probe (k = 0.4 N/m, f0 = 70 
kHz, Bruker).  AFM images were processed with Nanoscope Analysis 8.15 software (Bruker).  
Samples were prepared by deposition of a solution of nanoparticles in nanopure water (50 µL, 
0.2 mg/mL) onto freshly cleaved mica substrates.  After 1 min, excess solution was wicked away 
by a piece of filter paper, and the mica surface was allowed to dry in air. 
2.2.3 Experimental procedures 
Synthesis of PBYP.  Synthesis and characterization of the cyclic phosphotriester 
monomer BYP was performed according to a previously reported procedure.19  A solution of 
BYP (0.9910 g, 5.631 mmol) and 3-azido-1-propanol (48.4 mg, 0.479 mmol) in anhydrous DCM 
(2 mL) was transferred via syringe into a flame-dried vial equipped with a stir bar and rubber 




(82.3 mg, 0.592 mmol) in anhydrous DCM (0.2 mL) was injected quickly into the vial.  After 
stirring for 20 min, the reaction vial was opened to air, and quenched by addition of excess acetic 
acid.  An aliquot of the reaction mixture was withdrawn and diluted with CDCl3 to determine the 
BYP monomer conversion by 31P NMR spectroscopy, by comparison of the relative integrations 
of the peaks at 17.97, and between -0.20 and -1.89 ppm, corresponding to cyclic and ring-opened 
phosphoester resonances, respectively.  PBYP was purified by precipitation from DCM into 
diethyl ether and then dried under vacuum to afford a colorless liquid (893.6 mg, 85 % yield).  
1H NMR (500 MHz, CDCl3): δ 4.47-3.93, 3.83-3.66 (m, POCH2CH2O, POCH2CH2C≡CH, 
N3CH2CH2CH2), 3.42 (t, N3CH2, J = 5.0 Hz), 2.64-2.51 (br, CH2C≡CH), 2.18-2.02 (br, 
CH2C≡CH), 1.92 (q, N3CH2CH2, J = 5.0 Hz) ppm.  
13C NMR (126 MHz, CDCl3): δ 79.56, 70.84, 
66.46, 65.82, 65.02, 47.58, 29.63, 20.64 ppm.   31P NMR (202 MHz, CDCl3): δ -0.2 to -1.89 ppm.  
FT-IR (ATR) 3700-3100, 3100-2700, 2100, 1711, 1647, 1456, 1375, 1271, 1230, 1009, 964, 800, 
733 cm-1.  Tg = -37 °C.  TGA in Ar: 170-310 °C, 57% mass loss; 310-500 C, 14% mass loss, 29% 
mass remaining at 500 °C.  SEC (0.01 M LiBr in DMF, PS standards): Mn = 14.9 kDa, Đ = 1.22.   
Post-polymerization modification of PBYP with L-cysteine via thiol-yne reaction to 
afford zwitterionic PBYP (zPBYP).  PBYP (941.8 mg, 5.1 mmol alkyne groups), L-cysteine 
(9.0595 g, 51.580 mmol), 2,2-dimethoxy-2-phenylacetophenone (DMPA, 395.0 mg, 1.541 
mmol), and concentrated HCl (11.65 M, 4.4 mL, 51 mmol) were dissolved in N,N-
dimethylacetamide (DMAc, 35 mL), deoxygenated under N2(g) for 10 min, and irradiated under 
UV light (365 nm) for 2.5 h with stirring.  The resulting solution was transferred to dialysis tubing 
(MWCO 3.5 kDa) and dialyzed against nanopure water adjusted to pH 3 with HCl at 4 °C for 1 
d to remove excess thiol and photoinitiator.  The solution was then lyophilized to afford zPBYP 




N3CH2CH2CH2, POCH2CH2O, POCH2CH2CH), 4.18-3.91 (br, CH2CH(NH3)COOH, 
POCH2CH2CH), 3.91-3.70 (POCH2CH2 in the anionic repeat units), 3.51 (t, N3CH2, J = 5.0 Hz), 
3.40-2.61 (br, SCHCH2S, SCHCH2S, CH2SCHCH2S, SCHCH2SCH2), 2.40-2.14, 2.06-1.72 (br, 
N3CH2CH2, POCH2CH2CH) ppm. 
 13C NMR (126 MHz, CDCl3): δ 172.06, 68.02, 67.21, 66.35, 
65.22, 64.50, 53.40, 47.28, 36.61, 36.21, 31.49, 29.03 ppm.  31P NMR (202 MHz, CDCl3): δ 1.10 
to -1.70 ppm.  FT-IR (ATR) 3140-2780, 2670, 2460, 1780, 1655, 1593, 1514, 1472, 1362, 1285, 
1207, 1097, 991, 912, 843, 760 cm-1.  Tg = -64 °C.  TGA in Ar: 150-200 °C, 11% mass loss; 200-
400 °C, 46% mass loss, 43% mass remaining at 500 °C.   
Synthesis of citrate-coated AuNP (AuNP@citrate).  Into a 20 mL glass vial equipped 
with a stir bar, nanopure water (5 mL), HAuCl4 (10 mM, 500 µL) and sodium citrate solution 
(20 mM in nanopure water, 500 µL) were added and allowed to stir.51  Ice-cold, freshly-prepared 
sodium borohydride solution (20 mM in nanopure water, 1 mL) was then quickly added to the 
mixture while vigorously stirring at rt.  The solution turned pink after a short time, indicative of 
formation of AuNPs, and was stirred for an additional 0.5 h.  The AuNPs were then purified by 
centrifugal filtration (MWCO 10 kDa) with nanopure water three times at 3500 rpm.   
Preparation of zPBYP-coated AuNP (AuNP@zPBYP).  In a typical reaction, zPBYP 
(1.0 mg) was dissolved in 1× PBS (pH = 7.4, 1 mL).  A solution of AuNP@citrate (2 mL, 0.14 
mg/mL Au as determined by ICP-MS) in nanopure water was then added dropwise into the 
solution of zPBYP using a syringe pump over 5 min while stirring.  The reaction mixture was 
stirred for 3 h, and the polymer-coated NPs were purified by centrifugal filtration (MWCO 10 
kDa) with nanopure water three times at 3500 rpm.   
Preparation of PEG-coated AuNPs (AuNP@PEG).  In a typical reaction, TA-PEG-




AuNP@citrate (2 mL, 0.14 mg/mL Au) was then added dropwise into the solution of TA-PEG-
OMe using a syringe pump over 5 min while stirring.  The reaction mixture was stirred for 3 h, 
and the PEG-coated NPs were purified by centrifugal filtration (MWCO 10 kDa) with nanopure 
water three times at 3500 rpm. 
Preparation of shell-crosslinked zPBYP-coated AuNP (AuNP@X-zPBYP).  To a 
solution of AuNP@zPBYP (2 mL, 0.14 mg/mL Au, 0.44 µmol of carboxylic acids, 0.44 µmol of 
amines), a solution of 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide methiodide (EDCI, 650 
µL, 0.10 mg/mL in water) was added.  The reaction was allowed to stir overnight at rt, and the 
crosslinked nanostructures were purified by centrifugal filtration (MWCO 10 kDa) with 
nanopure water three times at 3500 rpm.   
Hydrolytic degradation of zPBYP.  In a typical study, a lyophilized sample of zPBYP 
(15.1 mg) was dissolved in D2O (0.4 mL) and transferred into an NMR tube.  The sample was 
maintained in a New BrunswickTM Innova® 44 incubator shaker (37 ºC, 60 rpm) and 
characterized by 31P NMR to monitor the degradation progress at predetermined times (0 h, 1 d, 
2 d, 3 d, 4 d, 6 d).  The study was repeated in triplicate.  After 6 d, an aliquot of the sample was 
diluted with methanol and further characterized by ESI-MS for identification of small-molecule 
degradation products.  The remaining sample was dialyzed against nanopure water in dialysis 
tubing (MWCO 1 kDa), followed by lyophilization to determine the amount of residual material 
retained in the dialysis tubing.   
Degradation study of AuNP@zPBYP, in comparison to AuNP@citrate, 
AuNP@PEG, and AuNP@X-zPBYP.  In a typical study, a solution of AuNP@zPBYP was 
kept in the incubator shaker (37 ºC, 60 rpm) and characterized by UV-Vis spectroscopy at 




AuNP@PEG, and AuNP@X-zPBYP in the incubator shaker was evaluated by monitoring the 
surface plasmon resonance (SPR) over 14 d.  
Cytokine multiplex assay.  The multiplex assay was performed as reported previously.49  
RAW 264.7 (2 × 104 cells/well) mouse macrophages were plated in a 96-well plate in Dulbecco’s 
Modified Eagle Medium (DMEM) (10% fetal bovine serum and 1% penicillin/streptomycin) and 
incubated at 37 ºC and 5% CO2 for 24 h.  The medium was then replaced with fresh medium 1 h 
prior to the addition of 20 µL of each of the samples (medium (control), AuNP@citrate, 
AuNP@zPBYP, AuNP@PEG, and AuNP@X-zPBYP (5 µg/mL Au in each sample)).  After a 
24 h incubation, the supernatants were collected and centrifuged for 10 min at 13000 rpm.  Serial 
dilutions of cytokine standards (Bio-Rad Laboratories, Inc., Hercules, CA) were prepared in cell-
culture medium to generate a calibration curve with which to determine cytokine concentration.  
The cytokine standard and cells treated with culture medium (control, 50 µL) and NPs (50 µL) 
were incubated with antibody-conjugated magnetic bead solution (50 µL) for 30 min in the dark.  
After washing, the detection antibody solution (50 µL) was added to the wells and incubated in 
the dark for 30 min under continuous shaking (300 rpm).  After washing, streptavidin-
phycoerythrin solution (50 µL) was added to each well and incubated while protected from light 
for 10 min under continuous shaking (300 rpm).  Finally, after several cycles of washing, re-
suspension in the assay buffer and shaking, the expression of the mouse cytokines, interleukin 
(IL)-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (P40), IL-12 (P70), IL-13, IL-17, 
eotaxin, granulocyte-colony-stimulating factor (G-CSF), granulocyte macrophage-colony 
stimulating factor (GM-CSF), interferon-γ (IFN-γ), keratinocyte-derived chemokine (KC), 
monocyte chemotactic protein (MCP)-1, macrophage inflammatory protein (MIP)-1α, MIP-1β, 




tumor necrosis factor-α (TNF-α) were measured immediately using a Bioplex 200 system, 
equipped with high-throughput fluidics (HTF) and a Pro II Wash station, and the data were 
analyzed using Bioplex Data Pro software.  Cytokine expression was reported relative to that by 
cells in culture medium.   
Cytokine adsorption assay.  Adsorption of the mouse cytokines, IL-1α, IL-1β, IL-2, IL-
3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (P40), IL-12 (P70), IL-13, IL-17, Eotaxin, G-CSF, GM-
CSF, IFN-γ, KC, MCP-1, MIP-1α, MIP-1β, RANTES and TNF-α onto the AuNPs, was measured 
using a Bioplex 200 system equipped with HTF and a Pro II Wash station.  Specific 
concentrations of the cytokine standards were determined either in cell culture medium (DMEM) 
or when mixed with the various NPs (5 µg/mL) in the same medium, as described previously.44, 
52  The values are reported in Figure 6 as the ratio of the cytokine concentration in the 
cytokines/NP mixtures to that in samples without NPs treated and subjected to the same rinsing 
procedures. 
2.3 Results and Discussion 
2.3.1 Design and synthesis of the zwitterionic polyphosphoester, zPBYP   
The zPBYP was designed as an alternative AuNP coating material to PEG, with 
zwitterions in the side chains to prevent biofouling and undesired immune system responses, and 
an azide group at the chain end to enable attachment of drugs, targeting moieties, and imaging 
agents (Figure II.1).  A PPE backbone was selected due to its previously reported 
biocompatibility, degradability, and chemical versatility.19  The chain length was set to be 




previously-reported TA-PEG-OMe (DPn = 12), which stabilized ultrasmall NPs, with number-
average hydrodynamic diameters (Dh(number)) < 10 nm postulated to promote effective renal 
clearance in vivo.53  The azide group on the chain end, while not utilized in this work, provides 
opportunities for further modification of the polymer via azide-alkyne click reactions to expand 





Figure II.1.  Synthesis of PBYP, followed by post-polymerization modification via a thiol-yne 
click reaction with L-cysteine to yield the zwitterionic polyphosphoester zPBYP, and the 
subsequent preparation of AuNP@zPBYP and AuNP@X-zPBYP.  Inset:  SEC trace of PBYP in 
DMF.   
 
 







The alkyne-functionalized homopolymer PBYP was synthesized by rapid 
organocatalyzed ring-opening polymerization (ROP) of the cyclic phosphotriester monomer 
BYP at rt in DCM with 3-azidopropanol as the initiator and DBU as the organocatalyst (Figure 
II.1).  After 20 min, the reaction was quenched by addition of excess acetic acid.  The 31P NMR 
spectrum of the reaction aliquot showed almost complete conversion of the single cyclic 
monomer signal (resonating at 18.0 ppm) to several polymer 31P resonance frequencies (between 
-0.2 to -1.9 ppm) (Figure II.2).  Size exclusion chromatography (SEC) of the purified product 
(Figure II.1 inset) revealed a monomodal molar mass distribution with relatively narrow 
dispersity (Đ = 1.22), consistent with the controlled character of organocatalyzed ROP to yield 
well-defined polymers.  The number-average molar mass (Mn) and degree of polymerization 
(DPn) were calculated from the 
1H NMR spectrum of PBYP (Figure II.3), by comparing the 
integration of the proton resonances from the initiator (3.4 ppm) with those of the polymer side 











Figure II.4.  NMR spectroscopy of zPBYP in D2O: (a) 
1H NMR (500 MHz) and (b) 31P NMR 




The zwitterionic polymer, zPBYP, was synthesized by post-polymerization modification 
of PBYP via photoinitiated thiol-yne click reaction of PBYP with excess L-cysteine (10 eq. 
relative to alkyne groups), as shown in Figure II.1.  The similar solubility of L-cysteines and 
zPBYP in a variety of solvents rendered purification by precipitation unfeasible, therefore, the 
reaction mixture was dialyzed against water acidified with HCl (pH = 3) at 4 °C for 1 d to remove 
excess thiol and photoinitiator, then lyophilized to afford zPBYP as a white solid in 61% yield.  
The appearance of signals for protons adjacent to the L-cysteine sulfur atom, resonating between 
3.5 and 2.8 ppm, and the disappearance of the alkyne proton resonances (2.2-2.0 ppm) in the 1H 
NMR spectrum indicated quantitative consumption of the alkynes (Figure II.4a).  Following 
purification of zPBYP, the appearance of resonances between 1.1 and -0.4 ppm in the 31P NMR 
spectrum (Figure II.4b) indicated partial degradation, despite measures to inhibit degradation, 




nucleophilicity.  Nevertheless, given that the polymer was obtained in ca. 60% yield, which 
would presumably be substantially lower if the polymer had degraded into oligomers and been 
removed by dialysis, the degradation is assumed to occur predominantly by cleavage of side 
chains or near the chain ends.  The extent of degradation was determined to be ca. 20%, by 
comparing the integration of resonances of the phosphate groups between 1.1 and -0.4 ppm to 
the total integration of phosphorus resonances, i.e., from 1.1 to -1.7 ppm.  The multiple 
resonances from 4.0 to 3.7 ppm in the 1H NMR spectrum were assigned to the backbone protons 
in the anionic repeat units, consistent with our previously-reported NMR spectroscopy results on 
PPE ionomers.54  While degradation of zPBYP during purification was difficult to avoid, the 
presence of anionic groups was not anticipated to be detrimental to the stabilization of AuNPs.  
Taken together, the introduction of large amounts of zwitterionic L-cysteine groups onto 
biocompatible and degradable PPEs yielded promising PEG-alternative coating materials, which 
were then investigated for their ability to stabilize AuNPs and reduce immunotoxicity (vide 
infra).   
2.3.2 Synthesis of AuNPs with different coatings   
Citrate-coated AuNPs (AuNP@citrate) were prepared according to literature 
procedures,51 in which strong reducing agents are added to solutions of gold salts with stabilizing 
agents to produce small-sized AuNPs.  In a typical reaction, HAuCl4 and sodium citrate were 
mixed in nanopure water, followed by the addition of a freshly-prepared solution of NaBH4 in 
nanopure water (cooled in an ice bath prior to use) under vigorous stirring.  The solution was 
then allowed to stir at rt for 30 min before purification by centrifugal filtration.  Consistent with 




(Figure II.5, black trace) of AuNP@citrate at 510 nm, corresponding to the SPR of AuNPs.  TGA 
showed minimal mass loss for AuNP@citrate upon heating up to 500 °C under Ar (Figure II.6), 





Figure II.5.  Characterization of coated AuNPs in nanopure water by UV-Vis spectroscopy.   
 
 
Figure II.6.  TGA traces of AuNP@citrate (black trace), AuNP@X-zPBYP (red trace), 






Figure II.7.  TGA traces of TA-PEG-OMe (black trace), and AuNP@PEG (red trace), 




Polymer-coated AuNPs, AuNP@zPBYP and AuNP@PEG, were prepared by addition of 
AuNP@citrate dropwise into polymer solutions while stirring.  The reaction mixtures were 
stirred for 3 h at rt before purification by centrifugal filtration.  While PEG (TA-PEG-OMe) was 
anchored to the AuNPs by bidentate ligation of TA moieties at the chain end to the AuNP surface, 
zPBYP is postulated to displace citrate ligands and coat AuNPs by multivalent interactions 
between the thioether, carboxylic acid/carboxylate, and amine/ammonium groups58 of the side 
chains and Au atoms on the NP surface.  The UV-Vis spectra of both AuNP@zPBYP and 
AuNP@PEG showed broadening and a small red shift of the SPR peak (to 514 nm and 518 nm, 
respectively), relative to AuNP@citrate (Figure II.5).  In contrast to the negligible mass loss 
observed upon heating AuNP@citrate, the polymer coatings of AuNP@zPBYP and 
AuNP@PEG accounted for 26%, and 18% of the total mass, respectively, based on TGA (Figure 
II.6, 7).  It is noteworthy that the AuNP@citrate composites destabilized upon freezing, and black 
solids were observed after lyophilization that could no longer be dissolved in aqueous solution.  




solution.  These results indicated superior AuNP stabilization by the zPBYP and PEG coatings 
relative to citrate, attesting to the potential of these zwitterionic polymers as PEG-alternative 
coatings to enable storage and transport of therapeutically-relevant nanomaterials.   
As our previous work demonstrated a remarkable improvement of polymer NP stability 
and biocompatibility upon crosslinking,49 AuNPs with crosslinked polymer coatings, AuNP@X-
zPBYP, were prepared by adding a solution of EDCI in nanopure water to a solution of 
AuNP@zPBYP to mediate amidation of the carboxylic and amine groups in the L-cysteine side 
chains of zPBYP.  The solution was allowed to stir overnight before purification by centrifugal 
filtration with nanopure water.  By controlling the stoichiometry of EDCI (12 eq. relative to each 
polymer chain), ca. half of the reactive functionalities of the polymer coatings were postulated 
to undergo carbodiimide-mediated amidation, to achieve a shell crosslinking extent that has been 
demonstrated with improved in vivo blood retention of nanostructures.59  The UV-Vis spectrum 
of AuNP@X-zPBYP showed a broadened and further red-shifted absorption peak (528 nm) with 
respect to the uncrosslinked AuNP formulations (Figure II.5), attributed to a certain degree of 
inter-NP crosslinking to yield larger NPs.  Yet, no discernible precipitation was observed from 








Figure II.8.  TEM images and DLS size distributions of (a) AuNP@citrate, (b) AuNP@zPBYP, 
(c) AuNP@PEG, and (d) AuNP@X-zPBYP samples, scale bar = 5 nm.  Number-, intensity- and 
volume-averaged hydrodynamic diameters were obtained by DLS in nanopure water.   
 
 
Figure II.9.  AFM images and height profiles, plotting the height as a function of lateral distance 
along the red lines in the images, of (a) AuNP@citrate, Hav = 3.3 ± 0.7 nm, (b) AuNP@zPBYP, 
Hav = 3.6 ± 0.9 nm, (c) AuNP@PEG, Hav = 3.5 ± 0.6 nm, (d) AuNP@X-zPBYP Hav = 3.4 ± 0.8 
nm.  Samples were prepared by drop-casting AuNP solutions onto freshly-cleaved mica.  Scale 
bar = 100 nm.  
 
 
2.3.3 Evaluation of AuNP formulations by microscopy and light scattering   
The sizes of the coated AuNPs were assessed by TEM, DLS, and AFM to obtain 




depicted in Figure II.8, TEM images of AuNP@citrate, AuNP@zPBYP, AuNP@PEG, and 
AuNP@X-zPBYP suspensions showed circular shapes with narrow size distributions and 
average diameters (Dav) of 4.2 ± 0.6 nm, 3.9 ± 0.7 nm, 4.1 ± 0.6 nm, and 4.0 ± 0.6 nm, 
respectively, counting > 50 NPs.  Aggregation of NPs on the TEM grid was observed in the 
AuNP@citrate sample (Figure II.8a, left), which likely occurred during sample preparation.  In 
contrast, the increased spacing between the Au cores observed for the AuNP@PEG and 
AuNP@zPBYP samples is consistent with the larger polymer coatings (Figure II.8b, 8c, left), 
which effectively inhibited aggregation during sample drying on the TEM grid, further attesting 
to the superior stabilization abilities by these polymer coatings.  TEM of the AuNP@X-zPBYP 
structures (Figure II.8d) revealed some aggregation, resulting from either inter-NP crosslinking 
or aggregation upon drying due to the consumption of hydrophilic zwitterionic moieties during 
the crosslinking reaction.  DLS analyses (Figure II.8) revealed unimodal size distributions of all 
NP samples, indicative of the uniformity of these coating procedures.  The number-average 
hydrodynamic diameter (Dh(number)) of the AuNP@citrate nanostructure was determined to be 5 
± 1 nm.  After coating with zPBYP or TA-PEG-OMe, the Dh(number) of the NPs increased to 10 ± 
3 nm and 9 ± 2 nm, respectively.  The similar hydrodynamic diameters of the NPs validate the 
comparability between zPBYP and PEG coatings.  No significant increase was observed in the 
Dh(number) of AuNP@X-zPBYP, indicating that the desired intra-NP shell crosslinking was 
dominant over inter-NP crosslinking.   
AFM revealed globular structures from the AuNP@citrate, AuNP@zPBYP, 
AuNP@PEG, and AuNP@X-zPBYP samples (Figure II.9), with similar average heights of 3.3 
± 0.7 nm, 3.6 ± 0.9 nm, 3.5 ± 0.6 nm, and 3.4 ± 0.8 nm, respectively, counting > 50 NPs.  Overall, 




measured heights due to tip effects.  However, the larger diameters (ca. 50 nm) of the structures 
observed in the images of the AuNP@zPBYP, AuNP@PEG, and AuNP@X-zPBYP samples 
relative to those (ca. 25 nm) of the AuNP@citrate sample, are attributed to the spreading of the 
polymer coatings on the polar mica substrate.  Taken together, TEM, DLS, and AFM 
measurements indicate the successful, uniform coating of AuNPs with citrate and polymers, and 
these nanocomposites were further investigated to evaluate their immunotoxicity and cytokine 





Figure II.10.  Degradation kinetics of (a) zPBYP in D2O at 37 ºC, evaluated by 
31P NMR 










Figure II.11.  Degradation of zPBYP in D2O at 37 ºC, monitored by 




2.3.4 Degradation studies of zPBYP and AuNP@zPBYP   
Degradation kinetics of zPBYP were monitored by 31P NMR spectroscopy in D2O at 37 
ºC, acquiring spectra at predetermined times (Figure II.10a, 11).  These data showed that after 2 
d, hydrolysis of side chain and backbone units proceeded to an extent of ca. 75% in nanopure 
water (pH 5-6).  The formation of small-molecule products derived from the side-chain moieties 
and monomeric repeat units of zPBYP was confirmed by ESI-MS (Figure II.12).  After the 
degradation extent reached ca. 90% by 6 d, as determined by 31P NMR spectroscopy, the sample 
was dialyzed against nanopure water to remove small molecule products and lyophilized.  
Analysis of the material retained in the dialysis membranes indicated that 71 wt% of the polymer 




Figure II.12.  Identification of the side-chain moiety, and monomeric repeat unit in the 
degradation products of zPBYP by ESI-MS analysis, after 2 d incubation in D2O at 37 ºC and 
dilution with CH3OH.  
Figure II.13.  UV/Vis spectra of (a) AuNP@citrate, (b) AuNP@PEG, and (c) AuNP@X-zPBYP, 
at 0 d and 14 d incubation in H2O at 37 ºC, respectively.   
Degradation of AuNPs with different coatings was also evaluated at 37 ºC, monitoring 
changes in the SPR peak by UV-Vis spectroscopy.  From 0 h to 14 d, the SPR peak of the 
AuNP@citrate, AuNP@PEG, and AuNP@X-zPBYP did not change appreciably (Figure II.13), 
indicating the relative stability of these NPs.  In comparison, the SPR peak of AuNP@zPBYP 




Continued monitoring of the uncrosslinked AuNP@zPBYP from 4 to 14 d showed the SPR peak 
to broaden further and red-shift significantly, indicating aggregation of the NPs (Figure II.10b).  
Small amounts of precipitate were observed after 14 d.  These results demonstrate both the 
degradability of the zPBYP coatings and the effectiveness of shell-crosslinking to increase 
stability.  The degradable coatings are expected to be particularly appealing in biomedical 
contexts by alleviating safety concerns associated with long-term accumulation of non-
degradable macromolecular materials.   
2.3.5 Evaluation of immunotoxicity and anti-biofouling properties   
The immunotoxicity of the AuNP formulations was evaluated by incubating RAW 264.7 
mouse macrophages with various formulations for 24 h, followed by measuring the expression 
levels of twenty-three cytokines using a previously established multiplexing assay.44  The in vitro 
immunotoxicity was evaluated in terms of cytokine overexpression by cells exposed to NP 
formulations relative to that in those not exposed to NPs, indicative of the level of inflammatory 
immune response.  No significant overexpression of any of the twenty-three tested cytokines was 
observed in the presence of all four AuNP formulations relative to the control (data not shown).  
These results demonstrated the low immunotoxicity of the coated AuNPs, suggesting the 
biocompatibility of these zPBYP coatings and supporting their viability as alternative coating 







Figure II.14.  Cytokine adsorption on the coated AuNP formulations, calculated based on 
apparent concentrations of cytokines measured after incubation with NPs and subsequent rinsing 
to remove unadsorbed material, as compared to the concentrations in a solution containing no 




Adsorption of cytokines onto AuNPs was calculated based on the apparent concentration 
of cytokines measured after incubation with NPs and subsequent rinsing steps to remove 
unadsorbed cytokines, as compared to their concentrations in samples subject to the same 
procedures without NPs.  The two-dimensional heatmap (values normalized to the control levels) 
in Figure II.14 shows the results of cytokine adsorption assay, where red squares indicate lower 
cytokine adsorption in heatmap (i.e. from red to green, adsorption becomes higher).  Notably, the 
AuNP@zPBYP formulations exhibited the lowest cytokine adsorption out of all the NP 
formulations, while reduced adsorption was also measured for AuNP@PEG compared to 
AuNP@citrate, which displayed significant cytokine adsorption.  While the crosslinked 
formulations demonstrated low immunotoxicity and higher stability, they exhibited higher 
cytokine adsorption compared to the uncrosslinked counterparts, probably due to the presence of 
larger NPs, as well as the consumption of charged moieties upon crosslinking, rendering the 




zPBYP constructs will involve lowering the crosslinking degree to achieve a balance between 
NP stability and reduced cytokine adsorption.   
2.4 Conclusions 
The zwitterionic PPE, zPBYP, was designed and synthesized to afford a promising 
alternative to PEG as an AuNP coating material, offering hydrolytic degradability, favorable 
immunotoxicity and antifouling properties.  Organocatalyzed ROP of the cyclic phosphotriester 
monomer, BYP, with 3-azidopropanol as the initiator, yielded the alkyne-functionalized PPE 
with a monomodal molar mass distribution.  Functionalization of the alkynes in the side chains 
of the polymer with L-cysteine via thiol-yne click reactions yielded zPPEs.  Despite minor 
degradation of the polymer during purification by dialysis, the installation of large amounts of 
zwitterions in the side chains yielded highly hydrophilic polymers, which were coated 
successfully onto AuNPs through multivalent interactions between the thioether, carboxylic 
acid/carboxylate, and amine/ammonium groups of the polymer side chains and the Au surface of 
the NPs.  AuNP@citrate was synthesized by addition of NaBH4 to a solution of HAuCl4 and 
sodium citrate, then AuNP@zPBYP and AuNP@PEG were prepared by coating the polymers 
onto AuNP@citrate, followed by crosslinking of AuNP@zPBYP cysteines to form AuNP@X-
zPBYP.  Morphological analysis of the coated AuNPs revealed similarly sized cores of ca. 4 nm, 
and increased hydrodynamic diameters of the polymer-coated AuNPs relative to the citrate-
coated AuNPs.  Degradation studies indicated hydrolysis of side chain and backbone units 
proceeded to an extent of ca. 75% over 2 d in nanopure water (pH 5-6), together with broadening 
and red-shifting of the SPR peak of AuNP@zPBYP over time.  The coated NPs exhibited 




the four AuNP formulations, followed by measuring the levels of twenty-three cytokines relative 
to those in cells incubated without NPs.  Cytokine adsorption studies showed AuNP@zPBYP 
had the best antifouling performance.  While the crosslinked AuNP@X-zPBYP nanostructures 
showed higher cytokine adsorption compared to their uncrosslinked counterparts, the low 
immunotoxicity of these materials suggests the biocompatibility of the crosslinking strategy.  
Future optimization of crosslinking degree will be conducted to balance NP stability and 




CHAPTER III  
CHEMICAL DESIGN OF BOTH A GLUTATHIONE-SENSITIVE DIMERIC DRUG GUEST 
AND GLUCOSE-DERIVED NANOCARRIER HOST TO ACHIEVE ENHANCED 
OSTEOSARCOMA LUNG METASTATIC ANTICANCER SELECTIVITY* 
 
3.1 Introduction  
Nanomedicine holds great potential to offer effective treatment against devastating 
diseases, by providing sustained release of significant quantities of therapeutic agents, especially 
when the route of administration allows for direct access to the diseased tissues.3, 7, 60-62  Yet, 
rational design of the chemical structures of the drug and drug carrier are still needed to overcome 
several challenges influencing the success of in vivo studies, such as potential adverse effects of 
long-term accumulations of the nanocarriers, off-target toxicity of the therapeutics to normal 
tissues, and the limited ability of nanomedicines to penetrate tumor tissues at a potentially lethal 
concentration.2, 63-65  
OS is the most common primary cancer of bone in children and adolescents aged 10-20 
years and the third most common cancer overall in adolescents, with no proven etiology and a 
high fatality rate (70% survival at 5 years for non-metastatic patients, and less than 30% for those 
presenting with metastasis).27-28  The predominant site of metastasis is the lung, followed by other 
                                                 
* Reprinted (adapted) with permission from “Chemical design of both a glutathione-sensitive dimeric 
drug guest and glucose-derived nanocarrier host to achieve enhanced osteosarcoma lung metastatic 
anticancer selectivity” by Su, L.; Li, R.; Khan, S.; Clanton, R.; Zhang, F.; Lin, Y. -N.; Song, Y.; Wang, 
H.; Fan, J.; Hernandez, S.; Butters, A.; Akabani, G.; MacLoughlin, R.; Smolen, J.; Wooley, K. L., J. 




bones.  Once micrometastases grow into recurrent, overt disease, tumors are often resistant to 
conventional chemotherapy, and unresectible recurrent disease is fatal.26, 66  Therefore, 
innovative strategies for prevention and treatment of the metastatic disease are of critical need.  
Recently, our group employed PTX-loaded polyphosphoester (PPE)-based polymeric micelles 
and shell cross-linked knedel-like nanoparticles (SCKs) as nanotherapeutics to treat OS lung 
metastases via aerosol-based delivery.16  The strategy could provide distribution of nanocarriers 
throughout the lungs and achieve sufficient pulmonary drug concentrations while avoiding 
dilutional and systemic effects seen in intravenous (i.v.) administration, with prolonged drug 
release and extended lung retention of the SCKs, owing to their crosslinked structure.  However, 
safety concerns regarding the PPE degradation products, limited tissue and cell penetration 
ability and off-target toxicity remained as key challenges.  Therefore, in this report, an anticancer 
drug delivery system with optimized chemical structures was designed and developed, where the 
chemistry of each component is tailored to accomplish specific tasks.  This system improves 
selectivity, enhances tumor penetration ability, and facilitates drug release in response to 
conditions associated with tumor microenvironment.   
Nanoparticles derived from biodegradable polymers, such as polyesters,67 polypeptides,9 
PPEs,14, 16, 68 and polycarbonates,12, 69 have gained increasing interest for nanomedicines, which 
reduce the potential for long-term accumulation and associated adverse effects.  Recently, our 
group employed functional glucose-derived polycarbonates (PGCs) to construct nanostructures 
with tunable sizes, surface charges, and morphologies, and that are, notably, capable of 
degradation into natural products, e.g., glucose, carbon dioxide, ethanol.20, 47  We expected that 
leveraging the PGC-derived nanostructures as nanocarriers would circumvent potential 




phosphoric acid upon hydrolytic degradation, while maintaining the advantages of degradability, 
biocompatibility, and versatile functionality, such as for dye-labeling.16  Furthermore, the steric 
bulk and increased hydrophobicity of the PGC backbone, relative to those of PPEs, were 
anticipated to enable extended drug release.   
In order to access tumors for intracellular delivery within lung tissue via inhalation, the 
nanocarriers need to be capable of penetrating the diffusion and absorption barriers of the airway 
mucus,70 lung epithelium,71 and tumor stroma.72  The diffusion/penetration capacity of drug 
carriers across these barriers is known to depend on the chemical composition, shape, and, in 
particular, the size and surface properties of the nanocarriers,1, 65 and in this work these attributes 
were tuned to achieve optimal effects.  Chan and coworkers reported the tumor permeation of 
PEGylated gold nanoparticles (GNPs)73 and tiopronin-modified GNPs74 to depend strongly on 
the size of the nanoparticles, where larger nanoparticles localized near the vasculature, while 
smaller nanoparticles diffused rapidly throughout the tumor matrix.  Similarly, diffusion across 
respiratory mucus has been shown to be greatly restricted for particles larger than 100 nm.75  
Given the vital influence of particle size on their penetration ability, we targeted nanocarriers 
with desirable diameters of less than 30 nm.3  Meanwhile, cationic charges were also shown to 
improve tumor penetration, due to nanoparticle-induced necrosis and resultant tumor cell density 
reduction,13, 76-78 which could be conveniently imparted into the PGC constructs via a facile thiol-
yne click reaction.  To mitigate undesirable characteristics of cationic polymers, including mucus 
binding and non-specific cell toxicity,67 PEG was conjugated as a hydrophilic shell.79   
As the concentration of GSH in cancer cells can be several times higher than that in 
normal cells,80-81 redox-responsive linkages have been extensively exploited in designing drug 




off-target release and associated toxicity.  For instance, disulfide-linked dimeric pro-drugs of 
camptothecin,82 doxorubicin82 and PTX83-84 were recently encapsulated within amphiphilic 
polymers (i.e., methoxy poly(ethylene glycol)-block-polylactide) or PEGylated phospholipids to 
formulate pro-drug-loaded micelles.  Advantageous properties were observed with these 
constructs, including reducing agent DTT-triggered in vitro drug release, enhanced anticancer 
efficacy, and reduced adverse effects.  Therefore, disulfide-linked dimeric diPTX pro-drugs were 
anticipated to allow for enhanced containment by the PGC-based nanocarrier, relative to PTX, 
owing to the larger size and redox-triggered sustained release.  The cationic charges installed 
between the hydrophilic shell and hydrophobic core of the PGC nanocarriers, were further 
anticipated to provide better access of the negatively-charged GSH to the core domain and 
diPTX.   
Co-assembly of the redox-responsive diPTX pro-drug with the cation- and PEG-modified 
PGCs yielded nanocarriers that facilitated precise control of intracellular drug delivery, which 
holds great potential to finely tune drug release kinetics for beneficial anticancer activity with 
minimal undesired release in normal tissue.  The anticancer efficacy as inhaled 
chemotherapeutics was evaluated both in vitro and in vivo, and the host-guest constructs 
exhibited improved tumor penetration and significant inhibition of tumor cell growth towards OS 
lung metastases with minimal side effects.  These results demonstrate the promise of 








3.2 Materials and methods 
3.2.1 Materials 
Bicyclic glucose carbonates, GC(EPC) and GC(EC),20 and pro-drug diPTX85 were 
synthesized according to previously reported procedures.  Dichloromethane (DCM) and 
N,N-dimethylformamide (DMF) were purified by passing through a solvent purification system 
(J. C. Meyer Solvent Systems, Inc., Laguna Beach, CA).  1,5,7-Triazabicyclo[4.4.0]dec-5-ene 
(TBD) was dried over CaH2 in tetrahydrofuran (THF), concentrated under vacuum and stored in 
a glovebox under Ar atmosphere.  Other chemicals and reagents were used as received from 
Sigma-Aldrich, Co. (St. Louis, MO) unless otherwise noted.  Dialysis membrane tubing with a 
molecular weight cut-off (MWCO) of 6-8 kDa was purchased from Spectrum Laboratories, Inc. 
(Rancho Dominguez, CA) and soaked for 5 min in nanopure water at room temperature before 
use.  MC3T3 mouse osteoblast precursor cells, Dulbecco's Modified Eagle's Medium (DMEM) 
and Minimum Essential Medium alpha (MEMα) medium were obtained from the American Type 
Culture Collection (Manassas, VA), with media additives (fetal bovine serum, 
penicillin/streptomycin) were purchased from Sigma-Aldrich (St. Louis, MO).  Osteosarcoma 
cells (SJSA-1) were provided by Dr. Hughes at MD Anderson Medical Center.   Cell culture 96-
well round bottom plates were purchased from Corning Costar Co. (Corning, NY).   
In order to establish an orthotopic xenograft mouse model of osteosarcoma, NOD/SCID 
IL2-R-gamma -/- mice (The Jackson Laboratory) aged 4-6 weeks (males and females) were 
injected in their left tibias while under isoflurane anesthesia (1-2% v/v in pure O2) with a 10 µL 
PBS suspension of 50,000 SJSA-1 cells (ATCC) constitutively labeled via lentiviral transfection 




histology ex vivo.  For this procedure, a 27 Ga syringe needle was drilled into the proximal 
epiphysis of the tibia and guided down the tibia about mid-way to the diaphysis, where the 
suspension was injected.  Five days following engraftment, the mice were given intraperitoneal 
injections of 0.15 mL of 30 mg/mL D-luciferin potassium salt (Bioworld) and imaged for optical 
signal 15 minutes later using a small-animal imaging cabinet (Xtreme In Vivo, Bruker).  X-ray 
images of the mice were also taken to provide anatomical reference.  Baseline metastatic burdens 
in the lungs were then determined by measuring the signal intensity in the chest region of each 
mouse.  The mice were then assigned to one of three groups, determined randomly but matching 
for similar average baseline lung signals among groups. 
3.2.2 Instrumentation 
1H NMR, 31P 1H NMR and 13C NMR spectra were recorded on a Varian Inova 500 
spectrometer interfaced to a UNIX computer using VnmrJ software.  Chemical shifts were 
referenced to the solvent resonance signals.   
FT-IR spectra were recorded on an IR Prestige 21 system (Shimadzu Corp., Japan), 
equipped with an ATR accessory, and analyzed using IRsolution v. 1.40 software.  
Size exclusion chromatography (SEC) eluting with THF was conducted on a Waters 
Chromatography, Inc. (Milford, MA) system equipped with an isocratic pump (model 1515), a 
differential refractometer (model 2414), and column set comprised of a PLgel™ 5 μm guard 
column (50 × 7.5 mm), a PLgel™ 5 μm Mixed C column (300 × 7.5 mm, Agilent Technologies) 
and two Styragel® columns (500 Å and 104 Å, 300 × 7.5 mm, Waters Chromatography, Inc.).  
The system was operated at 40 °C with a flow rate of 1 mL/min.  Data were analyzed using 




determined relative to polystyrene standards (300-467,000 Da) purchased from Polymer 
Laboratories, Inc. (Amherst, MA).  Polymer solutions were prepared at a concentration of ca. 3 
mg/mL with 0.05 vol% toluene added as a flow marker, and an injection volume of 200 μL was 
used.  
Thermogravimetric analysis (TGA) was performed under Ar atmosphere using a Mettler-
Toledo model TGA/DSC 1 with a heating rate of 10 °C/min.  Glass transition temperatures (Tg) 
were measured by differential scanning calorimetry (DSC) on a Mettler-Toledo DSC822® 
(Mettler-Toledo, Inc., Columbus, OH) under N2(g).  DSC measurements were performed with a 
heating rate of 10 °C/min and analyzed using Mettler-Toledo Stare v. 10.00 software.  The Tg 
was taken as the midpoint of the inflection tangent of the second heating scan.  
Inductively coupled plasma-mass spectrometry (ICP-MS) was performed on a 
PerkinElmer SCIEX ICP mass spectrometer ELAN DRC II, equipped with high-speed 
quadrupole, dynamic reaction cell (DRC) and axial field technology (AFT) to eliminate 
polyatomic interferences, using 1% HNO3 as the matrix and rhodium as the internal standard. 
Transmission electron microscopy (TEM) images were collected on a JEOL 1200EX 
operated at 100 kV, and micrographs were recorded using a SIA-15C CCD camera.  Samples for 
TEM were prepared as follows:  10 μL of dilute polymer solution in nanopure water was 
deposited onto a carbon coated copper grid, and after 1 min, excess solution was quickly wicked 
away by a piece of filter paper.  The samples were then negatively stained with a 1 wt% 
phosphotungstic acid (PTA) aqueous solution (10 µL).  After 30 s, excess staining solution was 
quickly wicked away by a piece of filter paper and the samples were left to dry under ambient 




Atomic force microscopy (AFM) was performed using a Multimode 8 system (Bruker) 
using a ScanAsyst-Air Silicon Nitride probe (k = 0.4 N/m, f0 = 70 kHz, Bruker).  AFM images 
were assessed with Nanoscope Analysis (Bruker).  For AFM sample preparation, the solution of 
nanoparticles in nanopure water (50 µL) at 0.1 mg/mL was deposited on the mica surface.  After 
1 min, the excess of the solution was quickly wicked away by a piece of filter paper, and the mica 
surface was allowed to dry in the air flow.   
Dynamic light scattering (DLS) measurements were conducted using a Delsa Nano C 
instrument from Beckman Coulter, Inc. (Fullerton, CA) equipped with a laser diode operating at 
658 nm.  Scattered light was detected at 165° and analyzed using a log correlator over 70 
accumulations for a 0.5 mL of sample in a glass size cell (0.9 mL capacity).  The photomultiplier 
aperture and attenuator were adjusted automatically to obtain a photon counting rate of ca. 10 
kcps.  The particle size distribution and distribution averages were calculated using CONTIN 
particle size distribution analysis routines in Delsa Nano 2.31 software.  The peak averages of 
intensity, volume and number distributions from 70 accumulations were reported as the average 
diameter of the particles.  All measurements were repeated 10 times.   
The zeta potentials of the nanoparticles were determined by a Delsa Nano C particle 
analyzer (Beckman Coulter, Fullerton, CA) equipped with a 30 mW dual laser diode (658 nm).  
The zeta potential of the particles in suspension was obtained by measuring the electrophoretic 
movement of the charged particles under an applied electric field.  Scattered light was detected 
at a 30 ° angle at 25 °C.  The zeta potential was measured at five regions in the flow cell and a 
weighted mean was calculated.  These five measurements were used to correct for electroosmotic 
flow induced in the cell due to the surface charge of the cell wall.  All measurements were 
repeated 3 times, and the zeta potential was reported as the average and standard deviation.   
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The concentrations of PTX, PTX-SH and diPTX were determined by high performance 
liquid chromatography (HPLC) on a Shimadzu Prominence system equipped with an SPD-20AV 
prominence UV-Vis detector set to 227 nm and a Waters X Bridge C8 column (4.6 × 150 mm, 5 
µM, 100 Å) eluting in 60% acetonitrile and 40% 20 mM ammonium acetate buffer in isocratic 
mode.  The flow rate was set to 1 mL/min with a run time of 20 min, and the column temperature 
was set to 40 °C.  The HPLC method employed an external calibration of PTX, PTX-SH and 
diPTX.  
To measure the tumor-killing efficacy of the treatments, the tumor spheroids were imaged 
at 200× magnification on a laser scanning confocal microscope (FV-1000, Olympus) with laser 
lines of 488 nm (calcein-AM “live” stain), 543 nm (ethidium homodimer-1 “dead” stain), and 
635 nm (IRDye® 800CW conjugated to micelles) in depth scanning mode (step size = 10 μm) at 
a resolution of 256 × 256 pixels.  Image analysis was performed in ImageJ (NIH, v. 1.50i) using 
the Bio-Formats package (v. 5.5.0).  Maximum intensity z-stack projections of the fluorescent 
images were overlaid on their corresponding transmitted light images, which were also acquired 
on the confocal microscope using a transmitted light detection unit (Olympus) and the 635 nm 
laser.  The cross-sectional area of each spheroid was determined by drawing a region of interest 









The mouse nose-only nebulization system was designed by Dr. Akabani’s group in 
collaboration with Aerogen, Ltd using a prototype mesh nebulizer specifically designed for 
rodents (Figure III.1).  The mesh nebulizer was characterized with a next-generation impactor 
and was shown to have a mass median aerodynamic diameter (MMAD) of 2.171 with a geometric 
standard deviation (GSD) of 2.037.  Modeling was performed in Solidworks CAD software and 
exported as a stereolithography file (STL) (Figure III.1).  The exported STL file was then sent to 
the engineering innovation center at Texas A&M University.  The 3D printer chosen was the 
Stratasys EDEN 260V, which has a build volume of 255 × 252 × 200 mm (10.0 × 9.9 × 7.9 in.) 
with a 16-micron layer accuracy and 7-micron dimensional accuracy.  The materials chosen were 
a soluble support material, which could be removed with ultrasonic bath and/or water-jet, along 
with Objet VeroWhite (Stratasys, Ltd.), which is a rigid opaque material with 1.1-1.5% water 
absorption.  The nebulization system was made entirely from 3D printed VeroWhite Polyjet 




A cylindrical mouse bed was designed to hold the nebulizer, which fit at the top where 
the flow was biased towards the mouse nose and mouth.  This was accomplished by making the 
nebulizer holder cone-shaped and pushing isoflurane/O2 gas mixture into the system via 
independent ports in the back and removing flow from the system via slits near the mouth of the 
mouse to be used for removal of excess aerosol buildup and preventing condensation.  There 
were holes that would be capped in the front, on opposite sides of the nose to allow removal of 
soluble support material used in the 3D printing process.  Vacuum was also used to prevent 
contamination of the area surrounding the mouse body, preventing fur contamination.  There was 
a thin latex sheet with a slit near the front of the nebulizer system so that the mouse nose and 
throat tightly fit into the system. 
All experiments were performed according to institutional guidelines provided by Texas 
A&M's Environmental Health and Safety committee.  Experiments involving SJSA-1 and 
MC3T3 cell lines were performed according to guidelines provided by Texas A&M's 
Institutional Biosafety Committee for biosafety level 2 organisms (Protocol Approval Number 
IBC2014-075).  Animal studies were approved by the Texas A&M University, Institutional 
Animal Care and Use Committee (IACUC Protocol # 2016-0100). 
3.2.3 Experimental procedures 
Synthesis of 2- Synthesis of PEG113-b-[PGC(EC)12-co-PGC(EPC)4] (polymer 1).  The 
polymerization was carried out using standard glovebox and Schlenk line techniques.  Methoxy 
poly(ethylene glycol) (mPEG113), GC(EPC), and GC(EC) were dried under vacuum over P2O5 
for 3 days before transferring to a glovebox for storage under an inert atmosphere.  Stock 




-15 °C sodium chloride bath in a fume hood.  To a solution of GC(EPC) (60.1 mg, 0.161 mmol), 
GC(EC) (175.4 mg, 0.4816 mmol), and mPEG113 (200.7 mg, 0.04014 mmol) in 1.3 mL of DCM 
at -15 °C, was added organocatalyst TBD (2.8 mg, 0.020 mmol) in DCM (100 μL) under Ar 
atmosphere.  After stirring for 10 min, the reaction vial was opened to air and quenched by 
addition of Amberlyst 15 H-form resin.  The polymer was purified by precipitation from DCM 
into diethyl ether (3 ×) and dried under vacuum to afford the product as a white powder (404.6 
mg, yield 93%).  1H NMR (500 MHz, CDCl3) δ ppm 5.40 - 5.17 (dd, J = 10, 10 Hz, C
3H), 5.01 
(d, J = 6.5 Hz, C1H), 4.90 - 4.77 (m, C4H), 4.76 - 4.65 (m, C2H, OCH2CCH), 4.44 - 4.08 (m, 
C6H2, OCH2CH3 in sugar unit), 4.03 (s, C
5H), 3.63 (s, OCH2CH2 in PEG unit), 3.45 - 3.38 (m, 
OCH3 in sugar unit), 3.37 (s, OCH3 in PEG unit), 2.61 (s, OCH2CCH), 1.28 (td, J = 7.0, 3.0 Hz, 
OCH2CH3 in sugar unit).  
13C NMR (126 MHz, DMSO-d6) δ ppm 154.28, 153.95, 153.71, 96.17, 
78.91, 77.70, 73.74, 73.41, 72.49, 71.74, 70.25, 70.04, 66.83, 66.36, 64.93, 64.88, 64.75, 58.49, 
56.21, 55.42, 20.89, 14.30.  FT-IR (ATR) 3290, 3026 - 2779, 1750, 1466, 1371, 1343, 1241, 
1145, 1104, 1019, 962, 872, 841 cm-1.  Tg = -24, 98 °C.  TGA in Ar, 180 - 311 °C, 42% weight 
loss; 311 - 441 °C, 47% weight loss.  Mn (NMR) = 10.9 kDa.  Mn (SEC) = 12.1 kDa.  Đ = 1.12.  
Post-polymerization modification of PEG113-b-[PGC(EC)12-co-PGC(EPC)4] with 
cysteamine hydrochloride via thiol-yne reaction to afford polymer 2.  PEG113-b-[PGC(EC)12-
co-PGC(EPC)4] (200.5 mg, 18.41 μmol), cysteamine hydrochloride (167.2 mg, 1.473 mmol), 
and 2,2-dimethoxy-2-phenylacetophenone (DMPA, 47.2 mg, 0.184 mmol) were dissolved in 
anhydrous DMF (8 mL), deoxygenated under N2(g) for 30 min, and irradiated under UV light 
(365 nm) for 2 h.  The resulting copolymer solution was transferred to dialysis tubing (MWCO 
ca. 6-8 kDa) and dialyzed against nanopure water at 4 ºC for 3 d to remove excess thiol and 




[PGC(EC)12-co-PGC(Cys)4] as a white powder (205.2 mg, 95% yield).  
1H NMR (500 MHz, 
DMSO-d6) δ ppm 7.88 (br, SCH2CH2NH3Cl), 5.18 - 4.97 (m, C
1H, C3H), 4.95 - 4.70 (m, C2H, 
C4H), 4.42 - 4.05 (m, C5H, OCH2CHS, and OCH2CH3 in sugar unit), 4.03 - 3.88 (m, C
6H), 3.50 
(s, OCH2CH2 in PEG unit), 3.41 - 3.25 (m, OCH3, and OCH2CHS in sugar unit), 3.23 (s, OCH3 
in PEG unit), 3.14 - 2.56 (m, SCH2CH2NH3Cl, OCH2CHCH2S), 1.19 (td, J = 7.0, 3.0 Hz, 
OCH2CH3 in sugar unit).  
13C NMR (126 MHz, DMSO-d6) δ ppm 154.30, 153.97, 153.74, 96.19, 
73.74, 73.39, 72.56, 71.75, 70.26, 70.06, 66.76, 64.96, 64.77, 64.25, 60.16, 58.52, 55.37, 43.95, 
33.55, 29.35, 28.27, 15.07, 14.34.  FT-IR (ATR) 3549 - 3328, 3027 - 2795, 1749, 1466, 1371, 
1342, 1242, 1144, 1102, 1024, 962, 872, 841, 782 cm-1.  Mn (NMR) = 11.8 kDa.  Tg = -25, 92 °C.  
TGA in Ar, 180 - 311 °C, 43% weight loss; 311 - 441 °C, 51% weight loss. 
Azide-alkyne Huisgen cycloaddition of PEG113-b-[PGC(EC)12-co-PGC(EPC)4] with 
IRDye® 800CW azide to afford polymer 3.  A flame-dried Schlenk flask containing a magnetic 
stir bar was charged with PEG113-b-[PGC(EC)12-co-PGC(EPC)4] (17.1 mg, 1.58 μmol), IRDye® 
800CW azide (2.0 mg, 1.6 μmol), N,N,N,N,N-pentamethyldiethylenetriamine (PMDETA, 0.2 
mg, 2 μmol) and 5 mL of DMAc.  The reaction mixture was degassed by several freeze-pump-
thaw cycles (>3), during which copper(I) bromide (0.2 mg, 2 μmol) was added.  The flask was 
allowed to return to room temperature after the final cycle and stirred for an additional 4 h under 
N2.  The solution was subsequently filtered through a neutral alumina column and dialyzed in 
nanopure water containing Chelex® 100 resin in presoaked dialysis tubing (MWCO ca. 6-8 kDa) 
for 4 d to remove copper ions, followed by lyophilization to yield PEG113-b-[PGC(EC)12-co-
PGC(EPC)3-co-PGC(Dye)1] as a green powder (18.1 mg, 95% yield).  ICP-MS confirmed that 
less than 10 ppm copper was present in the polymer.  1H NMR (500 MHz, DMSO-d6) δ ppm 




J = 10, 10 Hz), 5.01 (d, J = 15.5 Hz), 4.83 (d, J = 15.5 Hz), 4.75 (s), 4.51 (s), 4.24 (s), 4.15 - 4.08 
(m), 3.99 (s), 3.79 (s), 3.49 (s), 3.38 - 3.26 (m), 3.22 (s), 2.70 (s), 2.03 (d, J = 8.5 Hz), 1.92 (s), 
1.76 (s), 1.63 (s), 1.51 (s), 1.30 (s), 1.18 (dt, J = 14.0, 7.0 Hz).  13C NMR (126 MHz, DMSO-d6) 
δ ppm 172.41, 154.48, 154.30, 153.95, 153.71, 150.30, 141.09, 137.87, 126.43, 125.95, 96.11, 
76.12, 73.68, 73.36, 72.46, 71.72, 70.23, 69.59, 69.10, 68.52, 67.91, 67.55, 66.80, 66.36, 64.88, 
64.75, 64.44, 64.23, 58.49, 55.36, 27.68, 27.64, 26.22, 21.08, 20.62, 14.39.  FT-IR (ATR) 3632 
- 3295, 3026 - 2773, 1754, 1466, 1398, 1371, 1342, 1241, 1168, 1099, 1060, 1019, 962, 873, 
841, 784 cm-1.  Mn (NMR) = 12.1 kDa. 
Preparation of diPTX-loaded nanoparticles with PEG-b-[PGC(EC)12-co-
PGC(Cys)4] and PEG-b-[PGC(EC)12-co-PGC(EPC)4].  In a typical experiment, diPTX (1.0 
mg), a mixture of cationic polymer PEG-b-[PGC(EC)12-co-PGC(Cys)4] and non-ionic polymer 
PEG-b-[PGC(EC)12-co-PGC(EPC)4] (10.1 mg) at a specific mass ratio, were dissolved in DMSO 
(100 µL).  This solution was then added dropwise into 9.9 mL nanopure water with vigorous 
stirring, to afford a series of diPTX-loaded nanoparticles.  The diPTX loading was determined 
by HPLC, which employed an external calibration of diPTX concentration against the peak area, 
while the sizes, morphologies, and surface characteristics were characterized by DLS, AFM, 
TEM and electrophoretic light scattering (Figure III.11).   
Determination of critical micelle concentrations (CMCs) for diPTX-loaded 
nanoparticles prepared with PEG-b-[PGC(EC)12-co-PGC(Cys)4] and PEG-b-[PGC(EC)12-
co-PGC(EPC)4].  The CMCs of the nanoparticles were determined by using pyrene as the 
fluorescent probe following the protocol previously reported by our group.  The sample solutions 
were prepared by mixing the micelle solution with the same volume of a pyrene aqueous stock 
solution (1.2 × 10-6 mol/L).  Samples with polymer concentrations ranging from 0.005 - 0.05 
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mg/mL were prepared.  All the sample solutions were stored at room temperature overnight to 
equilibrate the pyrene and the micelles.  The fluorescence measurement was conducted at room 
temperature, in which the pyrene was excited at 334 nm and its emission spectrum was recorded 
at 370 nm and 381 nm, corresponding to the first and third vibrational peaks, respectively.  All 
the measurements were repeated three times and the ratios of intensities of the first and third 
peaks were plotted against the total concentrations of the polymers in the sample solutions.  The 
CMC was measured to be 0.035 mg/mL, as the intersection of the tangent to the curve at the 
inflection with tangent through the points at high polymer concentration.  
Preparation of diPTX-loaded nanoparticles with PGC(EPC)-b-PGC(EC)-g-PEG2k 
(Figure III.2).  In a typical experiment, diPTX (1.0 mg) and PGC(EPC)-b-PGC(EC)-g-PEG2k 
(10.1 mg) were dissolved in DMSO (100 µL).  This solution was then added dropwise into 9.9 
mL nanopure water with vigorous stirring to afford diPTX-loaded nanoparticles.  The diPTX 
loading was determined by HPLC, while the size, morphology, and surface characteristic were 
characterized by DLS, TEM and electrophoretic light scattering (Figure III.2).  Hydrodynamic 
diameters of the diPTX-loaded micelles in nanopure water were measured by DLS:  Dh(intensity) = 
90 ± 53 nm, Dh(volume) = 30 ± 16 nm, Dh(number) = 19 ± 5 nm; zeta-potential:  -6 ± 1 mV; diameter 





Figure III.2.  The structures of the neutral polymer PGC(EPC)-b-PGC(EC)-g-PEG2k and the 




In vitro drug release studies of the diPTX-loaded PGC micelles.  In a typical 
experiment, the diPTX-loaded micelle solution (3 mL) was transferred into a presoaked dialysis 
cassette (Slide-A-Lyzer, 10 kDa MWCO, Pierce Biotechnology, Rockford IL).  The cassette was 
allowed to stir in 200 mL PBS (pH 7.4, 37 °C), containing either DTT (10 mM), GSH (10 mM), 
or no reducing agents.  Aliquots (0.5 mL) of the surrounding PBS solution were taken at pre-
determined times and analyzed by HPLC.  PBS with the same volume and composition was 
added to the dialysis solution outside the cassette after removal of each sample.  The release 
profiles of the diPTX-loaded micelles were obtained by monitoring the concentration increase of 
PTX, PTX-SH and diPTX over time in the surrounding PBS solution by HPLC.  The release 
study was conducted in triplicate.   
Preparation of formulations for cytotoxicity and SJSA-1 spheroid studies.  In a 
typical experiment, diPTX pro-drug (1.0 mg), PEG-b-[PGC(EC)12-co-PGC(Cys)4] (8.1 mg), and 
PEG113-b-[PGC(EC)12-co-PGC(EPC)3-co-PGC(Dye)1] (2.1 mg) were dissolved in 100 µL 
DMSO with a PTX concentration of 10 mg/mL.  Predetermined amounts of this solution were 
added dropwise into PBS or media to afford the stock solutions for cytotoxicity and spheroid 




2D cytotoxicity assays.  Osteosarcoma cells SJSA-1 (5 x 103 cells/well) and mouse 
osteoblast precursor cells MC3T3-E1 (5 x 103 cells/well) were plated in 96-well plates in DMEM 
and MEMα media, respectively (10% fetal bovine serum, and 1% penicillin/streptomycin).  Cells 
were incubated at 37 C in a humidified atmosphere containing 5% CO2 for 24 h.  Culture 
medium was replaced with serial dilutions of the polymers (100 µL) in fresh medium (PTX final 
concentrations ranged from 8.7 nM - 18 µM).  The PTX, diPTX, diPTX-loaded micelles and 
unloaded micelles (ƒpolymer 1 = 0.2) stock solutions were prepared in DMSO.  The cells were 
incubated with the formulations for 72 h and then the medium was replaced with 100 μL of fresh 
medium prior to addition of 20 μL MTS combined reagent to each well (Cell Titer 96® Aqueous 
Non-Radioactive Cell Proliferation Assay, Promega Co., Madison, WI).  The cells were 
incubated with the reagent for 2 h at 37 C in a humidified atmosphere containing 5% CO2 and 
were protected from light.  Absorbance was measured at 490 nm on a SpectraMax M5 
spectrometer (Molecular Devices Co., Sunnyvale, CA).  The cell viability was calculated based 
on the relative absorbance to the control untreated cells.  The 0% and 100% cell viabilities were 
considered as the control medium (no cells) and cells with no treatment, respectively.  The IC50 
values were calculated using the GraphPad Prism four-parameter fit (GraphPad Software, Inc., 
La Jolla, CA). 
SJSA-1 Spheroid studies.  Osteosarcoma cells (SJSA-1) were seeded in round-bottom, 
ultra-low attachment spheroid microplates (Corning) at a density of 500 cells per well in 100 μL 
DMEM/F-12 DMEM media supplemented with 10% fetal bovine serum and 100 U/mL 
penicillin, 200 μg/mL streptomycin and 0.25 μg/mL Fungizone.  Spheroids were formed after 
incubating at 37 °C, 5% CO2 overnight.  An additional 50 μL of PTX, diPTX, diPTX-loaded 




prepared in the same feeding media, was then added to the wells.  In order to dissolve diPTX and 
PTX in media, 0.25 vol% DMSO was added.  Following incubation for 7 d, the spheroids were 
stained with LIVE/DEAD® stain (calcein-AM with ethidium homodimer-1) per assay 
instructions. 
In vivo and ex vivo studies.  The efficacy of the diPTX-loaded cationic PGC micelles as 
an inhaled chemotherapeutic agent was evaluated in an orthotopic mouse model of human OS.  
NOD/SCID IL2-R-gamma -/- mice (The Jackson Laboratory), aged 4-6 weeks, were injected 
with firefly-luciferase and GFP-expressing SJSA-1 cancer cells (50,000 cells/mouse) in their left 
tibias, which was then allowed to progress and metastasize over a period of 5 days.  At 5 days 
post-injection, baseline bioluminescence signal in the lungs was measured (Bruker Xtreme In 
Vivo) for each mouse, which were then assigned randomly into 3 treatment groups:  Sham Control 
(PBS), diPTX pro-drug (0.18 mg/mL in 95% PBS / 5% DMSO), and the diPTX-loaded cationic 
PGC micelles (0.18 mg/mL diPTX in PBS).  To deliver the treatments, a custom-made 
nebulization/anesthesia chamber with a vibrating-mesh nebulizer (Aerogen) was used to produce 
a fine inhalable mist (~1 micron droplet size) that the mice breathed in while under isoflurane 
anesthesia (Figure III.1).  The nebulized doses, 1 mL in volume exposed to the mice over a period 
of about 20 minutes per mouse, were administered starting six days after the tumor injection and 
repeated 1, 2, 3, 4, 6, 8, and 10 days thereafter.  Fluorescence imaging of the mice in vivo (ex. 
760 nm / em. 830 nm) was performed to verify the uptake of the nanoparticles into the lungs 1 
day following the first nebulization.  Further bioluminescence imaging was performed on days 
12 and 19 after engraftment in order to track the progression of the lung metastatic burden.  On 
day 19, the mice were euthanized via CO2 asphyxiation and dissected to recover the lungs and 
other organs.  The lungs were inflation fixed by intratracheal instillation of 4% neutral buffered 
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formalin for 30 minutes, followed by submersion in 15% sucrose in PBS and then 30% sucrose 
for an additional 30 minutes each.  The lungs were then carefully dissected into their 5 distinct 
lobes, placed in cryomolds with O.C.T. media (Tissue-Tek®, Sakura® Finetek), imaged for 
fluorescence (ex. 760 nm / em. 830 nm), and then snap frozen in a dry-ice and 100% ethanol 
slurry for cutting and imaging using confocal microscopy. 
For microscopic analysis, the frozen tissue was sliced into 20 micron sections using a 
cryostat (Cryotome, ThermoFisher Scientific) at -15 °C.  The sections were mounted onto slides 
and coverslipped with optical medium (Fluoromount-G, ThermoFisher Scientific).  For some 
slides, DAPI was added to visualize the cellular nuclei.  Slides were stored at 4 °C until imaging. 
Confocal-microscope imaging (Fluoview FV1000, Olympus) was performed in order to 
evaluate the distribution of nanoparticles within the lung tissue with reference to the GFP-labeled 
tumors.  Images were acquired using a 10× air objective with laser excitations at 488 nm (GFP) 
and 635 nm (NIR) along with a transmission light detection unit and Nomarski DIC to visualize 
the lung structures in high detail.  Imaging of the entire lung slices was achieved with a motorized 
XY stage (Prior Scientific) and the Olympus FV10 software.  Mosaic stitches of the entire lung 
sections were analyzed for intensity using ImageJ.  
3.3 Results and Discussion 
3.3.1 Rational design of the diPTX-loaded PGC anticancer drug delivery system  
Sugar-derived nanocarriers with near-infrared (NIR) labels and a cationic segment 




core were synthesized and used to encapsulate diPTX pro-drugs with redox-responsive disulfide 
linkages (Figure III.3).  In designing the nanocarrier structure to optimize cancer cell-specific 
drug delivery, PGC building blocks were selected due to their biocompatibility, degradability, 
functionality, and ability to assemble into versatile nanostructures with varied sizes, charges and 
functionalities.20  Cationic moieties were incorporated within the PEG-protected nanocarriers to 
allow negatively-charged GSH to more readily access the core domain and to interact with the 
encapsulated diPTX, realizing preferential drug release in cancer cells with high GSH 
concentrations, while simultaneously increasing the tumor penetration ability and substantially 
reducing toxicity typically associated with cationic nanocarriers.86-87  Once the disulfide bond in 
the diPTX pro-drug is cleaved by a reducing agent, the thiol-terminated PTX derivative (PTX-
SH) undergoes hydrolysis to release the free drug.85  In addition, the dimeric size of the pro-drug 
was expected to allow for enhanced containment by the nanocarrier to provide for sustained 
release.  Co-assembly of non-ionic and cationic polymers was performed for the dual purposes 









Figure III.3.  Schematic illustration of the co-assembly of polymer 2 and polymer 3 with diPTX, 
and redox-responsive drug release to enable treatment of SJSA-1 multicellular tumor spheroids 
(MCTSs) with improved penetration, relative to free drug PTX, and pro-drug diPTX.   
Figure III.4.  Synthesis of polymer 1, PEG113-b-[PGC(EC)12-co-PGC(EPC)4] by ROP of 
GC(EC) and GC(EPC), followed by post-polymerization modification via a thiol-yne click 
reaction with cysteamine hydrochloride to prepare the cationic polymer 2, PEG113-b-
[PGC(EC)12-co-PGC(Cys)4], or via CuAAC to afford NIR dye-labeled polymer 3, PEG113-b-
[PGC(EC)12-co-PGC(EPC)3-co-PGC(Dye)1].  Inset:  Normalized SEC traces of polymer 1, 
macroinitiator mPEG113, and a mixture of the bicyclic carbonates GC(EC) and GC(EPC) with a 
molar ratio of 3:1 in THF. 
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Figure III.5.  1H NMR spectrum of PEG113-b-[PGC(EC)12-co-PGC(EPC)4] (polymer 1) (500 
MHz, CDCl3).  
3.3.2 Synthesis and post-polymerization modification of PEG-b-PGCs  
The functional and degradable diblock terpolymer 1, PEG113-b-[PGC(EC)12-co-
PGC(EPC)4], was synthesized by rapid organocatalyzed ring-opening polymerization (ROP) of 
the bicyclic glucose carbonates methyl-2,3-O-ethyloxycarbonyl-4,6-O-carbonyl-α-D-
glucopyranoside GC(EC) and methyl-2-O-ethyloxycarbonyl-3-O-propargyloxycarbonyl-4,6-O-
carbonyl-α- D-glucopyranoside GC(EPC) at -15 °C in dichloromethane (DCM) with mPEG113 as 
the macroinitiator and 1,5,7-triazabicyclo[4.4.0]-dec-5-ene (TBD) as the organocatalyst (Figure 
III.4).  The monomer feed ratio [GC(EC)] : [GC(EPC)] was set to 3 : 1 to provide sufficient
hydrophobicity and functionality.  The reaction was quenched by addition of Amberlyst 15 H-
form resin after 10 min, and size exclusion chromatography (SEC) (Figure III.4 inset) of the 
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crude product showed no remaining monomers, indicating quantitative conversions of both 
monomers.  The lower retention time of polymer 1 relative to mPEG113 confirmed the successful 
chain extension to afford the expected diblock terpolymer.  SEC further revealed monomodal 
molecular weight distribution and low dispersity (Đ = 1.12), demonstrating the well-defined 
structure of the diblock terpolymer.  The number-average molecular weight (Mn) and degree of 
polymerization (DPn) of each monomer were calculated from the 
1H NMR spectrum (Figure 
III.5) acquired after isolation of the polymer by precipitation, by comparing the integration of the 
CH2CH2O proton resonances (3.63 ppm) from the macroinitiator with the intensities of the 
resonances of protons attached to the anomeric carbons (5.01 ppm) and alkyne groups (2.59 ppm) 
in the PGC segment.  Differential scanning calorimetry (DSC) revealed two glass transition 
temperatures (Tg) at -24 and 98 °C, corresponding to the mPEG and PGC segments, respectively.  
Figure III.6.  1H NMR spectrum of PEG113-b-[PGC(EC)12-co-PGC(Cys)4] (polymer 2), with an 
inset showing an expansion of the region where the protonated amine resonance is observed (500 
MHz, DMSO-d6).  
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Figure III.7.  13C NMR spectrum of PEG113-b-[PGC(EC)12-co-PGC(Cys)4] (polymer 2) (126 
MHz, DMSO-d6).  
The cationic terpolymer 2, PEG113-b-[PGC(EC)12-co-PGC(Cys)4], was prepared by post-
polymerization modification of 1 via photoinitiated thiol-yne click reaction with a large excess 
of cysteamine hydrochloride (20 equivalents relative to alkyne groups) (Figure III.4).  The 
reaction mixture was dialyzed against nanopure water at 4 °C for 3 d to remove excess thiol and 
photoinitiator, then lyophilized to afford the product as a white powder in 95% yield.  The 
presence of the cysteamine proton resonances at 2.66, 2.82, 2.99 and 7.88 ppm in the 1H NMR 
spectrum and the disappearance of the alkyne carbon resonances at 78.91 and 77.70 ppm in the 
13C NMR spectrum indicated the consumption of the alkyne groups (Figure III.6, 7).  Fourier 
transform infrared (FT-IR) spectroscopy further confirmed the consumption of the alkynes and 
the introduction of amine groups (Figure III.8).  Glass transitions of polymer 2 were observed at 
-25 and 92 °C in DSC thermograms, suggesting that self-assembled nanostructures would possess 
flexibility within a PEG shell (Tg = -25 °C) and stability of the PGC-based core (Tg = 92 °C).  
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Figure III.8.  FT-IR spectra of polymers 1-3 and bicyclic carbonate monomer GC(EPC) with 
alkyne C-H stretch highlighted.  
Figure III.9.  1H NMR spectrum of PEG113-b-[PGC(EC)12-co-PGC(EPC)3-co-PGC(Dye)1] 
(polymer 3), with the unassigned peaks attributed to IRDye® 800CW (500 MHz, DMSO-d6).  
The NIR-labeled polymer 3 was obtained by grafting the hydrophilic NIR dye, IRDye® 
800CW azide, to polymer 1 via copper-catalyzed alkyne-azide coupling (CuAAC) in N,N-
dimethylacetamide (Figure III.4).  The reaction mixture was filtered through a neutral alumina 
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column and dialyzed against Chelex® 100 resin in nanopure water for 4 d to remove copper 
species.  Inductively coupled plasma-mass spectrometry (ICP-MS) confirmed the mass fraction 
of residual copper to be less than 10 ppm.  The appearance of a new resonance corresponding to 
the triazole proton at 8.12 ppm (Figure III.9) indicated successful conjugation of the IRDye® 
800CW to the polymer.  
3.3.3 Preparation of diPTX-loaded PGC nanoparticles  
PGC nanoparticles loaded with diPTX was achieved utilizing the previously described 
nanoprecipitation method.82, 88  Briefly, a series of mixtures of the non-ionic polymer 1 and 
cationic polymer 2 at predetermined mass ratios was first dissolved with diPTX (10 wt%) in 
DMSO, and then added dropwise into nanopure water with vigorous stirring to form diPTX-
loaded nanoparticles (conc. (polymer) = 1 mg/mL) with 1 vol% DMSO.  DiPTX loading was 
determined using high-performance liquid chromatography (HPLC), while the size, morphology, 
and surface charge were characterized by dynamic light scattering (DLS), atomic force 
microscopy (AFM), transmission electron microscopy (TEM) and electrophoretic light scattering 






Figure III.10.  Characterization of diPTX@CPGC.  a) Dh and Dav as a function of ƒpolymer 1, 
determined from DLS and TEM, respectively.  b) Zeta-potential of diPTX@CPGC in nanopure 
water and 0.1× PBS as a function of ƒpolymer 1.  Controls zeta potential measurements were 
acquired on unloaded PGC(EC)-b-PGC(Cys) in nanopure water and 0.1× PBS, and on physical 
mixtures of PGC(EC)-b-PGC(Cys) with mPEG113 in 0.1× PBS, from left to right.  c) Number-, 
intensity- and volume-based hydrodynamic diameter of diPTX@CPGC (ƒpolymer 1 = 0.2) in 
nanopure water measured by DLS.  d) TEM images of diPTX@CPGC (ƒpolymer 1 = 0.2) negatively 








Figure III.11.  Characterization of the nanoparticles prepared by loading diPTX in mixtures of 
polymers 1 and 2 by TEM (A1, B1, C1, D1, E1, and F1), AFM (A2, B2, C2, D2, E2, and F2), 
AFM height (A3, B3, C3, D3, E3, and F3) and DLS (A4, B4, C4, D4, E4, and F4) with ƒpolymer 1 
to be 0, 0.2, 0.4, 0.6, 0.8 and 1 from top to bottom.  The scale bars in the TEM images represent 





HPLC revealed that the physical encapsulation of 10 wt% diPTX was highly effective, 
with efficiencies > 98%.  Although this standard loading of 10 wt% diPTX was employed, 
preliminary experiments were found to allow for higher diPTX loading, to levels of ca. 40 wt%.  
As depicted in Figure III.11, DLS showed unimodal size distributions of all nanocarriers, 
suggesting the incorporation of polymer 1 and polymer 2 into the same nanostructures.  The 
number-average hydrodynamic diameter (Dh(number)) of the diPTX-loaded nanoparticles increased 
from 20 ± 5 nm to 110 ± 28 nm (Figure III.10a) as the mass ratio of the non-ionic polymer 1 
(ƒpolymer 1) increased from 0 to 1, owing to the increased hydrophobic content.  TEM and AFM 
images of diPTX-loaded nanoparticles with ƒpolymer 1 of 0 and 0.2 showed circular structures with 
average diameters (Dav) of 23 ± 5 and 30 ± 8 nm, respectively (counting > 50 nanoparticles) and 
heights of 4 ± 1 and 5 ± 1 nm (counting > 50 nanoparticles), respectively, suggesting the 
formation of micellar structures.  However, as the ƒ polymer 1 increased above 0.2, the morphology 
of the diPTX-loaded nanocarriers transformed from micelles to vesicles, indicated by the double 
layer structures observed in the TEM images, as well as the lower heights (3 ± 1 nm) in the AFM 
images (Figure III.11).  The hydrophobic diPTX pro-drug was anticipated to be encapsulated in 
the core of the micelles or in the double layer of the vesicles.  Zeta potential values (ξ) were 
characterized in nanopure water, 0.1× phosphate-buffered saline (PBS), and in 10 mM NaCl(aq).  
As shown in Figure III.10b, the ξ values measured for the five cationic nanocarriers were positive, 
ranging from 28 ± 2 mV to 16 ± 1 mV in nanopure water, while negative values of -5 ± 2 mV 
were obtained with the non-ionic nanoparticles, a common phenomenon observed for neutral 
polymer assemblies.19, 89  In both 0.1× PBS and 10 mM NaCl(aq) (data not shown), all nanocarriers 
showed negative ξ (< -10 mV), indicating PEG-like surface characteristics.  As a control, the 




showed positive ξ in all of these solutions, even when physically mixed with mPEG113 at a mass 
ratio of 1:1, further confirming that the positively-charged segment was protected by PEG.  
Recent studies suggest that cancer nanomedicines with smaller sizes exhibit enhanced in vivo 
performance due to greater tumor penetration.76  Thus, micelles with ƒpolymer 1 = 0.2 were chosen 
for subsequent release and cytotoxicity studies, as their size was less than 30 nm and ξ was 
relatively small (Figure III.10c, 10d).  Additionally, the small ratio of non-ionic, alkyne-






Figure III.12.  Characterization of the nanoparticles with diPTX loaded in PGC(EPC)-b-











Figure III.13.  Release of PTX, PTX-SH, and diPTX from (a, b, and c) diPTX-loaded cationic 
micelles (ƒpolymer 1 = 0.2), and (d, e, and f) diPTX-loaded PGC(EPC)-b-PGC(EC)-g-PEG2k 
micelles at 37 °C in PBS containing (a and d) 10 mM DTT, (b and e) 10 mM GSH, and (c and f) 




3.3.4 Evaluation of the drug release kinetics   
The drug release profiles of diPTX@CPGC were investigated in PBS in the presence or 
absence of reducing agents.  The non-ionic polymer PGC(EPC)-b-PGC(EC)-g-PEG2k (Figure 
III.2) reported recently by our group20 was utilized as a control to demonstrate the benefit of the 
positive charges residing at the core-shell interface on the diPTX release profile, as these 
nanocarriers exhibited similar sizes and physicochemical properties, as characterized by DLS, 
TEM, AFM (Figure III.12) and DSC.  For the drug release studies, the micelle solutions were 
diluted to yield diPTX concentrations of ca. 100 µg/mL, which were confirmed by HPLC.  The 
diPTX-loaded micelle solutions were then transferred into dialysis cassettes (MWCO 10 kDa) 




reducing agent.  The drug release profiles were obtained by monitoring the concentrations of 
PTX, PTX-SH, and diPTX in the surrounding PBS solution as a function of time, and the percent 
drug release was calculated based on the PTX equivalents determined by HPLC.  As depicted in 
Figure III.13, no diPTX release was observed in any of the solutions, consistent with results 
recently reported for other dimeric pro-drugs.82  No significant release of PTX or PTX-SH was 
observed from either the cationic (Figure III.13c) or non-ionic PGC micelles in the absence of 
reducing agents (Figure III.13f).  In the presence of 10 mM DTT, diPTX@CPGC afforded 
sustained and controlled release of free PTX, which plateaued at almost complete drug release 
within 3 d, during which the concentration of PTX-SH increased initially and later dropped 
(Figure III.13a).  Similar sustained and controlled release of free PTX was achieved in 10 mM 
GSH(aq), reaching a plateau at ca. 55% release in 2 d (Figure III.13b).  The incomplete release 
may be due to reduced interaction of core-encapsulated diPTX with the relatively bulky reducing 
agent GSH.  Yet, such release profiles, wherein relatively fast redox-responsive drug release over 
2 d, followed by slower and more sustained drug release expected upon degradation of the 
nanoparticles in the human body, are anticipated to be quite beneficial for drug delivery.  PTX 
release from the non-ionic PGC micelles in the presence of 10 mM DTT was slightly slower than 
that from diPTX@CPGC, reaching a plateau at ca. 85% release within 3 d and 50% release in 
ca. 20 h (Figure III.13d), slightly longer than the ca. 16 h required for 50% drug release from 
diPTX@CPGC.  The PTX release rate from the non-ionic PGC micelles in the presence of 10 
mM GSH, however, was much slower with only ca. 10% PTX release in 2 d and no significant 
increase over time (Figure III.13e), which may limit the potential of the non-ionic formulations 
as efficient drug delivery systems.  Taken together, the structure with positive charges confined 




GSH-mediated drug release profiles over analogous non-ionic nanocarriers.  Thus, 





Figure III.14.  Cytotoxicity of PTX, diPTX, cationic PGC micelles, and diPTX@CPGC in (a) 
SJSA-1 and (b) MC3T3 cells.  Cell viabilities are reported as an average of three measurements, 




3.3.5 Evaluation of nanoparticle toxicity   
The in vitro cytotoxicity of diPTX@CPGC was evaluated in SJSA-1 and MC3T3 cell 
lines, and compared to PTX (as a Taxol-mimicking formulation; Cremophor EL and ethanol, 1:1 
v/v), diPTX (prepared similarly to the PTX formulation, Cremophor EL and ethanol, 1:1 v/v), 
and cationic PGC micelles without diPTX (Figure III.14).  The cationic micelles exhibited 
negligible toxicity in both cell lines below 0.2 mg/mL, indicating the protective effect of PEG, 
which has been reported to improve the biocompatibility of cationic nanoparticles.19-20  In 
contrast, our earlier work with cationic PGC-based micelles, lacking a PEG shell, began showing 




cell lines.20  In SJSA-1 cells (Figure III.14a), diPTX@CPGC exhibited similar cytotoxicity to 
diPTX, which was slightly less toxic than the Taxol-mimicking formulation.  The reduced 
cytotoxicity of the diPTX formulations, in comparison with PTX, may be attributed to the 
relatively slow free drug formation and release.  As a result of the redox-responsive drug release 
mechanism, the cytotoxicity difference between diPTX and PTX was higher in non-cancerous 
cells, which are expected to have a less reducing intracellular environment (Figure III.14b).  
Accordingly, a higher IC50 value (0.14 mM PTX) was observed for diPTX relative to that 
measured for PTX (0.03 mM) in MC3T3 cells.  The toxicity of diPTX@CPGC was further 
reduced in the MC3T3 cells compared to unencapsulated diPTX and PTX, with an IC50 value of 
ca. 5 mM, demonstrating selectivity for killing cancer cells over non-cancerous cells.  These 
studies, thus, confirm the advantages of diPTX@CPGC as cancer-selective agents and highlight 





Figure III.15.  CLSM images of SJSA-1 MCTSs after treatment with PTX, diPTX, 
diPTX@CPGC containing 1.9-30 µM PTX, and cationic PGC micelles with equivalent polymer 
concentrations as used for the diPTX@CPGC, and PBS and DMSO controls (green: live cells, 






3.3.6 Nanoparticle toxicity in SJSA-1 spheroids   
Multicellular tumor spheroids (MCTSs) are versatile three-dimensional models for 
studying tumor biology and screening cancer therapeutics due to the MCTSs possessing a similar 
morphology, biological microenvironment, and response to chemotherapeutics as solid tumors 
in vivo.90-92  To test the effects of diPTX@CPGC on MCTSs, SJSA-1 human OS cancer cell-
derived MCTSs were established on low-binding U-shaped microplates, incubated with micelles 
or controls, and evaluated as an in vitro model to assess penetration capability and cell 
proliferation inhibition (Figure III.3, 15).  The MCTS growth inhibition provided by the different 
formulations, i.e., PTX, diPTX, diPTX@CPGC, and cationic PGC micelles (no drug/pro-drug), 
was monitored by confocal laser scanning microscopy (CLSM), and the concentrations of PTX 
in the drug/pro-drug formulations were determined by HPLC (Figure III.16).  PTX showed 
significant antitumor efficacy at concentrations from 1.9-30 μM PTX, with MCTS sizes reduced 
to ca. 50% of the controls at 1.9 μM PTX and ca. 20% at 30 μM PTX.  In comparison, the 
reduction of SJSA-1 MCTSs upon treatment with the diPTX pro-drug or diPTX@CPGC at 1.9 
μM was similar, ca. 25% of the controls.  At higher concentrations (3.8-30 μM PTX), the diPTX 
formulation reduced the MCTSs size to a greatest extent, achieving ca. 10% of the control tumor 
size with formulations containing 30 μM PTX, while the diPTX@CPGC reduced the MCTSs to 
a similar extent (ca. 20-25%) for all concentrations.  However, the live/dead staining results 
demonstrated that the remaining MCTSs incubated with diPTX still contained live cells at even 
the highest concentrations.  In contrast, diPTX@CPGC appeared to kill all cells at the highest 
concentration, likely resulting from improved penetration into the core of the MCTS.  Thus, the 




drug/pro-drug formulations.  The cationic PGC micelles without diPTX exhibited only slight 
anti-MCTS effect at the highest polymer concentration of 0.28 mg/mL, in which the amount of 





Figure III.16.  Growth inhibition of the SJSA-1 MCTSs by PTX, diPTX, diPTX@CPGC and 
the cationic PGC micelles (no drug/pro-drug) 7 d after addition of the formulations.  Cross 
sectional areas are reported as an average of four measurements, and error bars represent standard 




3.3.7 Nanoparticle efficacy against OS lung metastases   
An orthotopic xenograft mouse model was evaluated in order to determine the antitumor 
efficacy against OS lung metastases.  NOD/SCID IL2-R-gamma -/- mice (aged 4-6 weeks) with 
established lung metastases were nebulized with different formulations, including Sham Control 
(PBS), diPTX pro-drug (0.20 mg/mL in 95% PBS / 5% DMSO), and diPTX@CPGC (0.20 
mg/mL diPTX in PBS) (Figure III.1).  DMSO was necessary in order to obtain a stable 




bioluminescence signal of mice treated with micelles showed a ~40% reduction in the growth of 
the lung metastases over the study, relative to control group, while the ones treated with free 
diPTX showed no reduction on the lung metastases (Figure III.17a).  Possibly due to enhanced 
penetration and/or better retention in the lung, diPTX@CPGC exhibited a higher antitumor 
efficacy in the lung than did free diPTX.  The micelles also had a non-significant trend towards 
lower tumor burden at the primary site of metastases over control and free diPTX (Figure 






Figure III.17.  Relative OS tumor burden as measured by bioluminescence imaging, normalized 
to the baseline signal for each mouse, from a) the lung metastases and b) the primary tumor in 
the tibia after 7 and 14 d from the start of treatment.  A significant reduction in tumor progression 
was observed in the lungs for the mice treated with diPTX@CPGC (p = 0.038 vs. control, p = 
0.0114 vs. diPTX, one-way ANOVA with Tukey’s post-hoc comparison) but not with the free 
diPTX pro-drug (p = 0.7839).  No significant differences were observed for the tumor burden in 
the tibia.  c) Comparison of the metastases counted from histology of the different lung lobes ex 
vivo revealed a significant reduction in metastatic foci for the mice treated with diPTX@CPGC 
(p = 0.02 vs. control, two-way ANOVA with Tukey’s post-hoc comparison).  SL:  superior lobe;  
ML:  middle lobe;  IL:  inferior lobe;  PL:  post-caval lobe;  LL:  left lung.  d) Tracking of the 






Figure III.18.  Ex vivo fluorescence imaging showing the distribution of NIR signal (ex. 760 nm, 
em. 830 nm) in the lung lobes (from top left to bottom right: superior lobe, middle lobe, inferior 
lobe, and post-caudal lobe of right lung, left lung lobe, and trachea) following 14 days of 
nebulization treatments by control (A), diPTX pro-drug(B), and diPTX@CPGC (C).  Signal was 
well distributed throughout lung lobes of mice administered with diPTX@CPGC, whereas mice 
given control and diPTX pro-drug showed no signal. Some signal was also found in the trachea, 
though it is not distributed throughout.  Measurement of the signal per area (D) reveals that the 
left lung lobes tended to have the highest quantity of micelles.  SL:  superior lobe;  ML:  middle 
lobe;  IL:  inferior lobe;  PL:  post-caval lobe;  LL:  left lung.   
 
 
Figure III.19.  Ex vivo fluorescence imaging showing the distribution of NIR signal (ex. 760 
nm, em. 830 nm) in visceral organs and leg injected with tumor cells following 14 days of 
nebulization treatments.  Some signal was found in the liver, stomach, and intestines, however 









Thus, the diPTX@CPGC, appeared to predominantly exhibit a loco-regional anti-tumor 
effect in the lungs, with limited systemic effect.  Ex vivo imaging supported this conclusion, as 
high concentrations of micelles were found in the lungs, but not other organs or primary tumor 
(Figure III.18, 19).  While the lack of systemic antitumor effect may appear disadvantageous, we 
designed these nanocarriers for use as a potential replacement for the current osteosarcoma 
chemotherapy regimen, which is employed before and after surgical removal of the primary 
tumor in the bone.93  Currently, systemic chemotherapy is employed regardless of detection of 
metastases and typically consists of high-dose methotrexate, cisplatin, and doxorubicin.93  
Systemic chemotherapeutic regimens, however, are associated with acute and chronic toxic 
effects,94 including secondary malignancies.95  Use of lung-specific anti-cancer therapy may 
allow for a reduction in systemic chemotherapy, and thus a reduction in these adverse effects.96 
The in vivo bioluminescence data were supported by ex vivo measurements of the number 
of metastases per mm2 of lung tissue (Figure III.17c) after the mice were euthanized 19 d from 
the injection of the SJSA-1 cells.  Overall, diPTX@CPGC reduced the metastatic foci among the 
various lung segments (p = 0.02, two-way ANOVA with Tukey’s post-hoc comparison).  
Individual analysis of each lung segment revealed that some lung sections displayed a greater 
reduction than others, with the superior lobe of the right lung showing the least reduction.  This 
lobe also appeared to receive the least amount of nanoparticles by lung area (Figure III.18).  
Finally, the weights of the mice for the duration of the study (Figure III.17d) showed no 
significant differences between the groups, suggesting that the diPTX pro-drug and micelle 







Figure III.20.  CLSM images of lung histological sections of mice treated with diPTX@CPGC.  
NIR-labeled diPTX@CPGC (red) were found to reach the tumor sites and penetrate into the GFP-
expressing SJSA-1 tumors (green).  Additionally, diPTX@CPGC aggregates were found in the 
alveolar spaces, near blood vessels, and along the surfaces of the bronchioles, as revealed by 
DAPI nuclear staining (blue) and Nomarski DIC transmitted light imaging (greyscale).    
 
 
Figure III.21.  CLSM mosaic images of the distribution of diPTX micelles in the various mouse 
lung lobes.  Images were acquired using a 635 nm laser excitation source and automated scanning 
across the entire lobe.  The image pixel values were inverted for contrast.  Dark pixels represent 
areas with high fluorescence intensity.  Most of the micelles appeared to accumulate near the 







Figure III.22.  CLSM mosaics of 20 μm slices from the various mouse lung lobes from mice 
administered control (top panel), diPTX (middle panel), or diPTX@CPGC (bottom panel).  
Fluorescence from the SJSA-1 tumors (green) and NIR labeled micelles (red) are overlayed on 
transmitted light images of the full lung sections.  Distribution patterns of the nanoparticles 
showed higher abundance near the main branching airways.  Additionally, nearby lung 
metastases appeared fewer in number and/or smaller in size, indicating a loco-regional activity.  




































Evaluation of the NIR fluorescence signal for the lungs ex vivo (Figure III.18) revealed 
that a relatively higher dose of micelles reached the left lung lobe, as compared to the lobes in 
the right lung, though all lobes showed a discernible signal.  Microscopic examination of 20 µm 
lung slices via CLSM revealed that the micelles were well distributed throughout the various 
structures of the lung, including alveolar spaces, bronchi, blood vessels, and penetrating into 
tumor sites (Figure III.20).  Scans of the entire lung slices revealed that the micelles deposited 
primarily near the main branching airways, although micelles were found to extend to the 
periphery (Figure III.21, 22).  Sections of the lungs with high deposition of nanoparticles also 
appeared to have fewer and/or smaller tumors, providing further evidence of localized anti-cancer 
effect.  The deposition sites of the micelles appeared to show signs of aggregation (Figure III.20), 
with large spots of high micelle concentration relative to the measured size of individual particles.  
Similar aggregation patterns have been seen in other studies of lung delivery of nanoparticles.4, 
70, 97  The process and kinetics of this phenomenon, and whether it is specific to certain cell types, 
deserve further exploration.  Importantly, the micelles did show an apparent ability to bypass the 
respiratory epithelium and access the tumors.  Finally, only limited NIR signal was found in the 
other organs of the mice that were treated with micelle formulations (Figure III.19, 23), further 







Figure III.23.  In vivo fluorescence and x-ray imaging of diPTX@CPGC distribution 1 day 
following the first nebulized dose (ex. 760 nm, em. 830 nm).  A high proportion of micelles was 
found near the nares and head of the mice, as well in what appeared to be the digestive tract, 





Two PGC-based block polymers and one dimeric PTX pro-drug were designed to be co-
assembled into degradable, functional nanocarriers, where the chemistry of each component was 
defined to accomplish important tasks.  The well-defined diblock terpolymer PEG-b-PGC(EC)-
co-PGC(EPC) was synthesized by rapid ROP of glucose-derived monomers, with good 
biocompatibility, degradability and versatile functionality.  Cationic moieties were introduced by 
thiol-yne click modification of the PGC segment, to construct nanocarriers with enhanced tumor 
penetration ability, while undesirable characteristics of cationic polymers was mitigated by the 
PEG shell.  Disulfide-linked diPTX pro-drug was designed to allow for redox-triggered release 
in cancer cells with high GSH concentration, where the negatively-charged GSH can readily 
interact with encapsulated diPTX due to confined cationic charges in the shell-core interface or 




relative to PTX, to provide for sustained release.  A series of nanocarriers with different sizes, 
surface charges, and morphologies was constructed by tuning the mass ratio of the amphiphilic 
cationic PGC and an analogous NIR-labeled non-ionic polymer employed in co-assembly.  Given 
their suitable size, zeta potential and nanostructure, cationic PEG-b-PGC micelles with ƒpolymer 1 
= 0.2 were selected for in vitro studies, which showed controlled and sustained in vitro PTX drug 
release in the presence of GSH or DTT.  Cytotoxicity assays confirmed the biocompatibility of 
diPTX@CPGC, and significant selectivity of diPTX@CPGC for killing cancer cells over healthy 
cells.  Studies in SJSA-1 MCTSs demonstrated improved tumor penetration ability and 
anticancer efficacy of diPTX@CPGC relative to Taxol-mimicking formulations.  Therefore, the 
anticancer efficacy of diPTX@CPGC as inhaled chemotherapeutics was further evaluated in an 
orthotopic mouse model of human OS, with free diPTX and PBS as control groups.  The lung 
bioluminescence signal of mice 14 d after treatment with diPTX@CPGC was significantly lower 
relative to the PBS controls, demonstrating their capability to slow the growth of lung metastases.  
Throughout the duration of the study, no significant differences were observed in the weights of 
the mice in the treatment and control groups, indicating the tolerance of the diPTX pro-drug and 
the PGC micelles.  The micelles distributed appreciably throughout various structures of the lung, 
demonstrated by the ex vivo studies.  The ex vivo study results also confirmed a reduction of 
tumor growth after treatment with diPTX@CPGC, indicating the promise of diPTX@CPGC as 




CHAPTER IV  
FACILE CONSTRUCTION OF WELL-DEFINED JANUS NANOPARTICLES FROM 
FUNCTIONAL POLYPHOSPHOESTER BASED TRIBLOCK POLYMERS FOR 
ADVANCED SILVER THERAPEUTIC RELEASE 
 
4.1 Introduction  
Polymeric nanoparticles have been extensively investigated for therapeutic delivery, due 
to their unique properties such as the nanoscale size, high surface-to-volume ratio, and tunable 
physiological characteristics realized by their favorable chemical structures.  However, the 
translation of nanomedicine research into clinical use is technically challenging due to a few 
concerns, e.g. the high cost of industrial manufacture arising from the sophisticated chemistry, 
and possible batch-to-batch variation of the physical and chemical properties in large-scale 
production5-6.   
Despite the rapid development of modern pharmaceutical research, bacterial infections 
remain a great threat to human lives throughout the world21, 98.  Significant morbidity or mortality 
can be caused by serious infections without proper treatment.  According to the Centers for 
Disease Control and Prevention (CDC) of the United States, more than two million patients are 
infected with antibiotic-resistant bacteria each year, which directly results in at least 23000 deaths 
nationwide24.  To overcome treatment failures and increased severity of infections associated 
with the continually evolving resistant pathogens, development of novel antimicrobial 




Silver has been used as a bactericidal material for thousands of years.  Silver cations are 
demonstrated to be an effective antimicrobial agent with low toxicity to human tissues, while 
rare documented cases of bacterial resistance are reported.  Given the broad-spectrum 
antimicrobial activity, high efficacy and relatively low cost, various silver-based antimicrobial 
agents have been commercialized.  As the in vivo application of silver cation is limited due to its 
inactivation by salts and other biomolecules in the physiological condition, our group has 
developed a series of polymeric nanoscopic platforms to improve the bioavailability and efficacy 
of silver-based therapeutics.  Shell crosslinked knedel-like nanoparticles (SCKs) comprised of 
poly(acrylic acid)-block-polystyrene (PS-b-PAA) were first investigated for the delivery of silver 
cations, which, though showing lower efficacy in vitro, exhibited significantly enhanced 
antimicrobial efficacy in vivo as compared to the free drug101.  Furthermore, degradable and 
biocompatible polyphosphoester (PPE)-based nanocarriers were synthesized, which could 
reduce long-term accumulation of the polymers in the human body, while retaining the improved 
antimicrobial activity and lower toxicity in comparison to the free drug15, 102.  However, the 
production of ethylene glycol upon hydrolytic degradation remained a safety concern for these 
PPE systems synthesized from common five-membered ring phosphotriester monomers.   
4.2 Materials and methods 
4.2.1 Materials 
Dichloromethane (DCM) and tetrahydrofuran (THF) were purified by a solvent 
purification system (J. C. Meyer Solvent Systems, Inc., Laguna Beach, CA).  1,5,7-




and stored in a glovebox under Ar atmosphere.  Methoxy poly(ethylene glycol)45 (mPEG45) was 
purchased from RAPP POLYMERE (Tuebingen, Germany).  All other chemicals and reagents 
were used as received from Sigma-Aldrich, Co. (St. Louis, MO) unless otherwise noted.  Slide-
A-Lyzer dialysis cassettes (10 kDa MWCO) were purchased from Pierce Biotech. (Rockford, 
IL).  Nanopure water (18 MΩ·cm) was acquired from a Milli-Q water filtration system, Millipore 
Corp. (Bedford, MA).  RAW 264.7 mouse macrophage, Dulbecco’s Modified Eagle’s Medium 
(DMEM) were obtained from the American Type Culture Collection (Manassas, VA). Media 
additives (fetal bovine serum, penicillin/streptomycin) were obtained from Sigma-Aldrich (St. 
Louis, MO). Cell culture 96-well round bottom plates were purchased from Corning Costar Co. 
(Corning, NY). 
4.2.2 Instrumentation 
1H NMR, 31P NMR and 13C NMR spectra were acquired on a Varian Inova 500 
spectrometer interfaced to a UNIX computer using VnmrJ software.  Chemical shifts in the 1H 
NMR and 13C NMR spectra were referenced to the residual solvent resonance signals, while 
those in the 31P NMR spectra were referenced to an external standard, 85% H3PO4 in D2O.  
Fourier-transform infrared spectroscopy (FT-IR) spectra were recorded on an IR Prestige 21 
system (Shimadzu Corp., Japan), equipped with an attenuated total reflectance (ATR) accessory, 
and analyzed using IRsolution v. 1.40 software.   
Size exclusion chromatography (SEC) eluting with THF was conducted on a Waters 
Chromatography, Inc. (Milford, MA) system equipped with an isocratic pump (model 1515), a 
differential refractometer (model 2414), and a four-column set, including a PLgel™ 5 μm guard 




and two Styragel® columns (500 Å and 104 Å, 300 × 7.5 mm, Waters Chromatography, Inc.).  
The system was equilibrated at 40 °C with the flow rate set to 1.0 mL/min.  Data collection and 
analysis were performed with Breeze software (Waters Chromatography, Inc., Milford, MA).  
Molecular weights were determined relative to polystyrene standards (300-467,000 Da) 
purchased from Polymer Laboratories, Inc. (Amherst, MA).  Polymer solutions were prepared at 
a concentration of ca. 3 mg/mL with 0.05 vol% toluene added as a flow marker, and an injection 
volume of 200 μL was used.  
Thermogravimetric analysis (TGA) was performed under Ar atmosphere using a Mettler-
Toledo model TGA/DSC 1 with a heating rate of 10 °C/min.  Glass transition temperatures (Tg) 
were measured by differential scanning calorimetry (DSC) on a Mettler-Toledo DSC822® 
(Mettler-Toledo, Inc., Columbus, OH) under N2(g).  DSC measurements were performed with a 
heating rate of 10 °C/min and analyzed using Mettler-Toledo Stare v. 10.00 software.  The Tg 
was taken as the midpoint of the inflection tangent of the second heating scan.  
Inductively coupled plasma-mass spectrometry (ICP-MS) was performed on a 
PerkinElmer SCIEX ICP mass spectrometer ELAN DRC II, equipped with a high-speed 
quadrupole, dynamic reaction cell (DRC) and axial field technology (AFT) to eliminate 
polyatomic interference, using 1% HNO3 as the matrix and rhodium as the internal standard. 
Transmission electron microscopy (TEM) images were collected on a JEOL 1200EX 
operated at 100 kV, and micrographs were recorded using a SIA-15C CCD camera.  High-
resolution scanning transmission electron microscopy (STEM) and elemental mapping were 
conducted on a FEI Tecnai G2 F20 FE-TEM coupled with energy-dispersive X-rays (EDX), 
operating at a voltage of 200 kV and equipped with a Gatan CCD camera.  Samples for TEM 




carbon coated copper grid, and after 1 min, excess solution was quickly wicked away by a piece 
of filter paper.  Samples of the silver-loaded nanoparticles were imaged with no staining.  And 
the sample of empty nanoparticles was negatively stained with a 1 wt% phosphotungstic acid 
(PTA) aqueous solution (10 µL).  After 30 s, excess staining solution was quickly wicked away 
by a piece of filter paper.  The samples were then left to dry under ambient conditions overnight.   
Atomic force microscopy (AFM) was performed using a Multimode 8 system (Bruker) 
in PeakForce® tapping mode using a ScanAsyst-Air Silicon Nitride probe (k = 0.4 N/m, f0 = 70 
kHz, Bruker).  AFM images were processed with Nanoscope Analysis 8.15 software (Bruker).  
Samples were prepared by deposition of a solution of nanoparticles in MOPS buffer (50 µL) onto 
freshly cleaved mica substrates.  After 1 min, excess solution was wicked away by a piece of 
filter paper, and the mica surface was allowed to dry in air.   
Dynamic light scattering (DLS) measurements were conducted using a Delsa Nano C 
instrument from Beckman Coulter, Inc. (Fullerton, CA) equipped with a laser diode operating at 
633 nm.  Scattered light from 0.5 mL samples in a disposable polystyrene cell (0.9 mL capacity) 
was detected at 165° and averaged over 70 accumulations.  The photomultiplier aperture and 
attenuator were adjusted automatically to obtain a photon count rate of ca. 10 kcps.  The particle 
size distribution and distribution averages (i.e., the intensity-, volume-, and number-average 
hydrodynamic diameters) were calculated using CONTIN particle size distribution analysis 
routines in Delsa Nano 2.31 software.  All measurements were repeated 10 times.   
Electrospray ionization mass spectrometry (ESI-MS) experiments were performed using 
a Thermo Scientific LCQ-DECA instrument.  The sample was directly infused at a flow rate of 




were set to 50 and 10 arbitrary units, respectively.  The transfer capillary temperature was held 
at 250 °C.  Xcalibur 2.0 software was used for data acquisition and processing.   
All experiments were performed according to institutional guidelines provided by Texas 
A&M's Environmental Health and Safety committee.  Experiments involving mouse derived cell 
lines (RAW 264.7) were performed according to guidelines provided by Texas A&M's 
Institutional Biosafety Committee for biosafety level 1 organisms (Protocol Approval Number 
IBC2014-075). 
4.2.3 Experimental procedures 
Synthesis of 2-ethoxy-4-vinyl-1,3,2-dioxaphospholane-2-oxide (E4VP).  To a 
solution of triethylamine (18.7 mL, 13.6 g, 0.135 mol) in 200 mL of anhydrous THF at 0 °C, a 
solution of ethyl dichlorophosphate (9.9943 g, 0.061337 mol) in 20 mL of anhydrous THF, and 
a solution of 3,4-dihydroxy-1-butene (5.4146 g, 0.061453 mol) in 20 mL of anhydrous THF 
were dropwise added.  The reaction mixture was allowed to stir for 12 h.  After the complete 
conversion of ethyl dichlorophosphate as confirmed by 31P NMR, the reaction mixture was 
filtered and the filtrate was concentrated.  The concentrated filtrate was purified by vacuum 
distillation to afford the pure product as a colorless liquid (5.9 g, 59.7 % yield).  1H NMR (500 
MHz, CDCl3, ppm):  δ 1.23 (m, 3H, POCH2CH3), 3.95-4.16, 4.35-4.53 (m, 2H, OCH2CHO), 
4.16-4.30 (m, 2H, POCH2CH3), 4.91-5.10 (m, 1H, OCH2CHO), 5.38-5.59 (m, 2H, CHCH2), 
5.79-6.00 (m, H, CHCH2);  
13C NMR (126 MHz, CDCl3, ppm):  δ 16.21, 65.17, 70.13, 78.68, 
120.83, 132.34;  31P NMR (202 MHz, CDCl3, ppm):  δ 16.32, 16.44.  +ESI MS:  calculated 




One-pot synthesis of PEG45-b-PE4VP49-PLLA20 (polymer 1).  The polymerization 
was carried out using standard glovebox and Schlenk line techniques.  The mPEG45 and L-
lactide were dried under vacuum over P2O5 for 3 days before being transferred to a glovebox 
for storage under an inert atmosphere.  E4VP monomer was freshly prepared on the same day 
of polymerization.  Stock solutions were prepared in a glovebox under Ar atmosphere, while 
the ROP was conducted in an -15 °C sodium chloride bath in a fume hood.  To a solution of 
E4VP (1002.3 mg, 5.6294 mmol), and mPEG45 (224.7 mg, 0.1124 mmol) in 2.0 mL of DCM at 
-15 °C, was added the organocatalyst TBD (15.6 mg, 0.112 mmol) in DCM (0.1 mL) under Ar 
atmosphere.  After stirring for 30 min, additional DCM (3.0 mL) was added to dilute the 
reaction mixture.  An aliquot of the reaction mixture was taken out and quenched by addition of 
acetic acid in DCM, which was characterized by 31P NMR to determine the monomer 
conversion to be ca. 99%.  The solution of L-lactide (323.6 mg, 2.245 mmol) in DCM (0.3 mL) 
was then added.  After stirring for 5 min, the reaction vial was opened to air and quenched by 
addition of Amberlyst 15 H-form resin.  The monomer conversion of L-lactide was determined 
to be ca. 100% by analyzing an aliquot of the crude reaction mixture with 1H NMR.  The 
polymer was purified by precipitation from DCM into a mixture of pentane and diethyl ether 
(v/v =1:1, 3 ×) and dried under vacuum to afford the product as a white solid (1.30 g, yield 
84.2%).  1H NMR (500 MHz, CDCl3, ppm):  δ 1.30-1.41 (br, POCH2CH3), 1.57-1.65 (br, 
C(O)CHCH3), 3.40-3.42 (s, OCH3), 3.65-3.74 (br, CH2OCH2CH2OCH2), 4.04-4.26 (br, 
POCH2CH3, OCH2CHO), 4.90-5.10 (br, OCH2CHO), 5.14-5.24 (br, C(O)CHO) 5.33-5.58 (br, 
CH=CH2), 5.79-5.98 (br, CH=CH2).  
31P NMR (126 MHz, CDCl3, ppm):  δ -4.0-0.0 (br).  SEC 




Post-polymerization modification of polymer 1 with 3-mercaptopropionic acid via 
thiol-ene reaction to afford polymer 2.  PEG45-b-PE4VP49-b-PLLA20 (171.3 mg, 0.0126 
mmol), 3-mercaptopropionic acid (167.2 mg, 1.473 mmol), and 2,2-dimethoxy-2-
phenylacetophenone (DMPA, 47.2 mg, 0.184 mmol) were dissolved in anhydrous DMAc (8 mL), 
deoxygenated under N2(g) for 30 min, and irradiated under UV light (365 nm) for 2 h.  The product 
was purified by precipitation to remove the excess thiol and photoinitiator, followed by drying 
under vacuum to afford a viscous liquid (205.2 mg, 95% yield).  1H NMR (500 MHz, DMSO-d6, 
ppm):  δ 1.35-1.46 (br, POCH2CH3), 1.95-2.15 (br, C(O)CHCH3, POCHCH2CH2), 2.55-2.90 (br, 
POCHCH2CH2, POCHCH2CH2SCH2, POCHCH2CH2SCH2CH2), 3.38-3.39 (s, OCH3), 3.65-
3.68 (br, CH2OCH2CH2OCH2), 4.13-4.42 (br, POCH2CH3, OCH2CHO, OCH2CH), 4.70-4.85 
(br, C(O)CHO).  31P NMR (126 MHz, DMSO-d6, ppm):  δ -4.0-0.0 (br).  Yield:  91.7 %.   
Cytotoxicity assays of polymer 2.  RAW 264.7 mouse macrophages (2 × 104 
cells/well) were plated in a 96-well plate in Dulbecco’s Modified Eagle’s Medium (DMEM) 
(10% fetal bovine serum and 1% penicillin/streptomycin).  Cells were incubated at 37 °C in a 
humidified atmosphere containing 5% CO2 for 24 h.  Culture medium was replaced with a fresh 
medium prior to the addition of 120 µL serial dilutions of the polymer solutions (final 
concentrations ranging from 1.5-3000 µg/mL).  The stock solution of the polymer was prepared 
in PBS.  The cells were incubated with the polymer solutions for 72 h and then the medium was 
replaced with 100 µL of fresh medium prior to the addition of 20 µL MTS combined reagent to 
each well (Cell Titer 96® Aqueous Non-Radioactive Cell Proliferation Assay, Promega Co., 
Madison, WI).  The cells were incubated with the reagent for 2 h at 37 °C in a humidified 
atmosphere containing 5% CO2 protected from light.  Absorbance was measured at 490 nm 




calculated based on the relative absorbance to the control-untreated cells.  The 0% and 100% 
cell viabilities were considered as the control medium (no cells) and cells with no treatment, 
respectively.  The calculations of the IC50 values were performed using GraphPad Prism four-
parameter fit (GraphPad Software, Inc., La Jolla, CA).   
Synthesis of the Janus nanoparticles under UV irradiation.  Into a 5 mL vial charged 
with a stir bar, a solution of polymer 2 (PEG-b-PE4VP-b-PLLA, 1.0 mg/mL) and AgOAc (0.17 
mg/mL, 10 wt% of Ag relative to polymer 2) in MOPS buffer (pH = 7.4, 1 mL) was added and 
allowed to stir for 20 min.  The solution was then irradiated under UV (365 nm, 500 µJ/cm2) for 
2 min, 4 min, 6 min, or 10 min, respectively, while stirring.  The crude mixtures were 
characterized by TEM to investigate the reaction progress and product morphologies.  Well-
defined Janus nanoparticles were obtained as the product after 6 min UV irradiation, and the 
silver loading amount and efficiency was determined by ICP-MS.  The product was then washed 
by MOPS buffer (pH = 7.4) thoroughly using centrifugal filters (N > 3) to remove the free silver 
ions for further studies.   
Release of silver from the Janus nanoparticles.  Typically, 3 mL of the Janus 
nanoparticle was transferred into a presoaked dialysis cassette (Slide-A-Lyzer, 10 kDa MWCO, 
Pierce Biotechnology, Rockford IL), which was allowed to stir in 4000 mL nanopure water at 37 
°C.  Aliquots (0.1 mL) of the nanoparticle solution were taken at pre-determined times and 
analyzed by ICP-MS.  The release profiles of the silver-loaded micelles were obtained by 
monitoring the concentration decrease of silver in the cassettes over time.  The release study was 
conducted in triplicate.  A solution of silver acetate in MOPS buffer (pH = 7.4) was tested in the 




4.3 Results and Discussion 
In this chapter, an amphiphilic triblock polymer was designed and synthesized based on 
a novel phosphotriester monomer, 2-ethoxy-4-vinyl-1,3,2-dioxaphospholane-2-oxide (E4VP), 
which was capable of avoiding the potential drawback of the degradation product.  Silver-loaded 
Janus nanoparticles was then built based on the polymer with a well-defined morphology and 









The functional cyclic phosphotriester monomer, E4VP, was designed with a vinyl group 
attached to the five-membered ring, which was synthesized by annulation of 3,4-
dihydroxybutene with ethyl dichlorophosphate in the presence of triethylamine in 
tetrahydrofuran (THF) at 4 °C (Figure IV.1).  The product was purified by distillation under 




combination of analytical techniques including 1H and 31P NMR (Figure IV.1).  Similar to 
reported cyclic phospholane structures, two resonances at 16.44 and 16.32 ppm were observed 
in the 31P NMR spectrum of E4VP, attributed to geometric isomers arising from the 2-position 





Figure IV.2.  Synthesis of polymer 1, mPEG45-b-PE4VP49-b-PLLA20, followed by post-
polymerization modification via a thiol-ene click reaction with 3-mercaptopropionic acid to 
prepare the anionic polymer 2, mPEG45-b-PE4VP(anionic)49-b-PLLA20.  Inset:  SEC trace of 




The functional degradable triblock polymer 1, methoxy poly(ethylene glycol)-block-
poly(2-ethoxy-4-vinyl-1,3,2-dioxaphospholane-2-oxide)-block-poly(L-lactide) (mPEG45-b-
PE4VP49-b-PLLA20) was then synthesized by a rapid organocatalyzed one-pot sequential ring-
opening polymerization (ROP) of E4VP and L-lactide at -15 °C in dichloromethane (DCM) with 
mPEG45 as the macroinitiator and 1,5,7 triazabicyclo[4.4.0]-dec-5-ene (TBD) as the 




[mPEG] was set to be 50 : 20 : 1 to provide sufficient hydrophobicity and versatile functionality.  
The E4VP monomer was first polymerized at a relatively high concentration in DCM.  After 
nearly complete conversion (ca. 99%, monitored by 31P NMR) of E4VP in 30 min, additional 
DCM was added to dilute the reaction mixture, followed by the addition of L-lactide for the chain 
extension.  The reaction was quenched by addition of Amberlyst 15 H-form resin after 5 min, 
with the conversion of L-lactide to be ca. 100%, determined by 1H NMR.  SEC indicated 
monomodal molar mass distribution and low dispersity (Đ = 1.05), demonstrating the well-
defined structure of the triblock polymer.  The number-average molar mass (Mn) of the polymer 
and degree of polymerization (DPn) of each monomer were calculated from the 
1H NMR spectra 
(Figure IV.3) acquired after isolation of the polymer by precipitation, by comparing the 
integration of the CH2CH2O proton resonances (3.63 ppm) from the macroinitiator with the 
intensities of the resonances of protons in the methyl groups at and chemical shift in the PE4VP 
and PLLA segments, respectively.   
The anionic polymer 2, mPEG45-b-PE4VP(anionic)49-b-PLLA20, was prepared by post-
polymerization modification of 1 via a photoinitiated thiol-ene click reaction with an excess of 
3-mercaptopropionic acid (10 equivalents relative to the alkene groups) (Figure IV.2).  The 
polymer was purified by precipitation and dried under vacuum to afford a viscous liquid.  The 
disappearance of the alkene proton resonances at 6.0 - 5.3 ppm in the 1H NMR spectrum indicated 
the consumption of the alkene groups (Figure IV.4).  Tg of polymer 2 was observed at – 28 °C in 









Figure IV.3.  Characterization of polymer 1 by 31P and 1H NMR spectroscopy.   
 
 









Figure IV.5.  Characterization of the anionic PPE-based nanoparticles.  a) The TEM image of 
the nanoparticles negatively stained by 1 wt% phosphotungstic acid (PTA) aqueous solution.  b) 
Number-, volume- and intensity-average hydrodynamic diameters measured by DLS.  c) 
Cytotoxicity of the nanoparticles in the RAW 264.7 cell line.  Cell viabilities are reported as an 




Self-assembly of polymer 2 was investigated by directly dissolving polymer 2 into the 
MOPS buffer (pH = 7.4) to form anionic nanoparticles.  As depicted in Figure IV.5a, transmission 
electron microscopy (TEM) images displayed circular structures of the nanoparticles with an 
average diameter (Dav) to be 17 ± 3 nm.  Dynamic light scattering (DLS) showed a unimodal size 
distribution of the nanoparticles, with the number-average hydrodynamic diameter to be 21 ± 6 
nm (Figure IV.5b).  The anionic nanoparticles were then tested for their toxicity in the cancer 
cell line, RAW 264.7 mouse macrophage, at concentrations ranging from 1.5 to 3000 µg/mL.  
Similar to the previously reported anionic PPEs19, the nanoparticles showed minimal cytotoxicity 
at concentrations below 750 µg/mL, while reduced toxicity at 3000 µg/mL was observed, 








Figure IV.6.  Characterization of the mixture of polymer 2 and silver acetate solutions in the 




Silver loading was subsequently conducted by directly mixing solutions of the anionic 
PPE-based nanoparticles and silver acetate (10 wt% Ag relative to the polymer).  The TEM image 
of the crude mixture (no staining) indicated successful loading of silver into the nanoparticles 
with circular nanostructures (Figure IV.6).  The mixtures were allowed to stir under UV 
irradiation (365 nm, 500 µJ/cm2) for 2 min, 4 min, 6 min, and 10 min, respectively, which were 
then characterized by TEM (Figure IV.6).  The TEM images revealed the formation of snowman-
like Janus nanoparticles over time under the UV irradiation, until the appearance of large 







Figure IV.7.  Characterization of the silver-loaded PPE-based Janus nanoparticles.  a) The TEM 
image of the nanoparticles with no staining.  b) Number-, volume- and intensity-average 
hydrodynamic diameters of the nanoparticles measured by DLS.  c) The AFM image and d) AFM 




As shown in Figure IV.7a, the Janus nanoparticles consisted of two circular parts, 
showing the similar Dav to be ca. 14 nm, with different contrast under TEM.  It was inferred that 
the higher contrast part was the metallic silver nanoparticle reduced upon the UV irradiation, 
while the lower contrast part was the PPE-based micelle loaded with silver cations/cluster.  The 
interactions between the PE4VP segment functionalities and the silver species allowed for partial 
reduction of the silver cations with a proper amount of UV irradiation.  Due to the flexibility of 
the PPE-based polymer chains, it is hypothesized that the nucleation centers of the reduced silver 
were capable of joining each other and growing to a single spherical nanoparticle, to form the 
Janus nanostructure as a relatively stable state.  The proposed Janus nanostructure was further 




6 ± 2 nm, respectively (Figure IV.7c, d).  Compared to the empty micelles, DLS results indicated 
an increase of the number-average hydrodynamic diameter to be 31 ± 9 nm for the Janus 
nanoparticles (Figure IV.7b).  In comparison, the solution of silver acetate in the MOPS buffer 
without addition of the polymer did not generate the well-defined snowman-like Janus 
nanoparticles (Figure IV.8), but showed a small amount of precipitates on the stir bar under 





Figure IV.8.  Characterization of the solution of silver acetate in the MOPS buffer (pH = 7.4) 
after irradiation under UV (365 nm, 500 µJ/cm2) for 6 min by TEM.  Scale bar:  100 nm.  
 
 
Figure IV.9.  Drug release from the silver-loaded PPE-based Janus nanoparticles in nanopure 
water, with the solution of silver acetate as a control, measured in triplicate.  Error bars indicate 




The release of silver from the Janus nanoparticles was then evaluated, showing the 
improved drug release profile, with the solution of silver acetate utilized as a control.  The 
solutions were transferred into presoaked dialysis cassettes (MWCO 10 kDa) and dialyzed 
against nanopure water.  The drug release profiles were obtained by monitoring the decrease of 
silver concentrations in the cassettes as a function of time by inductively coupled plasma mass 
spectrometry (ICP-MS).  As depicted in Figure IV.9, an initial burst release (ca. 50%) of silver 
from the PPE-based nanoparticles was observed within 2 h, followed by much more controlled 
and sustained release of the remaining silver over ca. 2 d.  Such release profiles are anticipated 
to be quite beneficial for drug delivery, which also evidence our proposed mechanism for the 
Janus nanostructure.  In comparison, complete release of silver from the silver acetate control 
solution was observed within 1 h.   
4.4 Conclusions 
A facile, rapid and conveniently-controlled approach to synthesize silver-loaded PPE-
based Janus nanoparticles is reported.  The novel functional phosphotriester monomer, E4VP, 
was designed and synthesized through a one-step annulation reaction to address the safety 
concern of previous PPE systems on their hydrolytic degradation product, ethylene glycol.  The 
triblock polymer, mPEG-b-PE4VP-b-PLLA, was then afforded by a one-pot sequential 
polymerization of E4VP and L-lactide with mPEG as the initiator, followed by post-
polymerization modification via a thiol-ene click reaction to introduce carboxylic acid 
functionalities.  A mixture of the polymer and silver acetate solutions was irradiated under UV 
to achieve partial reduction of the silver cations.  Interactions between the polymer and silver 




AFM, with the reaction progress controllable by the irradiation time.  Within 2 h dialysis against 
nanopure water, ca. 50% of silver was released from the Janus nanoparticles, with the remaining 
silver released in a much slower manner over 40 h, which could be beneficial in treatment of 
bacterial infections.  Based on the facile and controllable synthetic approach, the optimal drug 
release profile demonstrates the promise of these well-defined silver-loaded PPE-based Janus 





CHAPTER V  
CONCLUSIONS AND FUTURE WORK 
5.1 Conclusions 
This dissertation is focused on the rational design and synthesis of biocompatible 
polymers, based on polyphosphoesters (PPEs) and poly(glucose carbonate)s (PGCs), to 
formulate advanced nanostructures as molecular nanoprobes and nanomedicines.  Towards the 
applications, two parts were highlighted:  (1) preparation of degradable, biocompatible 
zwitterionic polymeric coating materials for metal nanoprobes, as discussed in Chapter II, and 
(2) development of degradable and biocompatible nanocarriers for anticancer therapeutics or 
antimicrobials, as described in Chapters III and IV.   
In Chapter II, a zwitterionic PPE was designed and synthesized to achieve a promising 
alternative to PEG as an AuNP coating material, with hydrolytic degradability, favorable 
immunotoxicity and antifouling properties.  PPE with a monomodal molar mass distribution was 
prepared, followed by functionalization of the alkynes in the side chains of the polymer with L-
cysteine via thiol-yne click reactions to yield the zPPEs.  The installation of large amounts of 
zwitterions in the side chains yielded highly hydrophilic polymers, which were coated 
successfully onto citrate-coated AuNPs through multivalent interactions between the thioether, 
carboxylic acid/carboxylate, and amine/ammonium groups of the polymer side chains and the 
Au surface of the NPs.  Morphological analysis of the zPPE-coated and PEG-coated AuNPs 
revealed similarly sized cores of ca. 4 nm, and increased hydrodynamic diameters of the polymer-
coated AuNPs relative to the citrate-coated AuNPs.  Degradation studies of the zPPE-coated 




extent of ca. 75% over 2 d in nanopure water (pH 5-6), together with broadening and red-shifting 
of the surface plasmon resonance (SPR) peak over time.  Negligible immunotoxicity of the coated 
NPs was confirmed, as demonstrated by incubating RAW 264.7 mouse macrophages with the 
NPs, followed by measuring the levels of twenty-three cytokines relative to those in cells 
incubated without NPs.  The optimal antifouling performance of zPPE-coated AuNPs was 
demonstrated by cytokine adsorption studies.  The biocompatibility and advanced antifouling 
properties of the zPPE-coated AuNPs indicated the promise of zPPE as a novel coating material 
for metal nanostructures.   
In Chapter III, degradable, functional nanocarriers were designed based on two PGC-
based block polymers and one dimeric PTX (diPTX) pro-drug, where the chemistry of each 
component was defined to fulfill important tasks.  The well-defined diblock terpolymer was 
synthesized by rapid ROP of glucose-derived monomers with PEG as the macroinitiator, which 
showed good biocompatibility, degradability and versatile functionality.  Cationic moieties were 
introduced by thiol-yne click modification of the PGC segment, to achieve enhanced tumor 
penetration ability, while undesirable characteristics of cationic polymers was mitigated by the 
PEG shell.  The diPTX pro-drug was designed with a disulfide linkage to allow for redox-
triggered release in cancer cells with high GSH concentration, where the negatively-charged 
GSH can readily access the encapsulated diPTX due to the presence of cationic charges in the 
nanostructure.  Nanocarriers was constructed by co-assembly of the amphiphilic cationic PGC 
and an analogous NIR-labeled non-ionic polymer, which showed controlled and sustained in 
vitro PTX drug release in the presence of reducing agents.  The biocompatibility and significant 
cancer-killing selectivity of the diPTX-loaded cationic PGC micelles were confirmed by 




diPTX@CPGC relative to Taxol-mimicking formulations were further demonstrated by studies 
in SJSA-1 MCTSs.  The diPTX@CPGC further exhibited its significant anticancer efficacy as 
inhaled chemotherapeutics in an orthotopic mouse model of human OS, with free diPTX and 
PBS as control groups.  Throughout the study, the weights of the mice in the treatment and control 
groups did not change significantly, indicating the tolerance of the diPTX pro-drug and the PGC 
micelles.  The ex vivo studies showed appreciable distribution of the micelles throughout various 
structures of the lung, which also confirmed a reduction of tumor growth after treatment with 
diPTX@CPGC.  The anticancer selectivity of the formulation both in vitro and in vivo 
demonstrates its potential for treatment of OS lung metastases.   
In Chapter IV, well-defined silver-loaded PPE-based Janus nanoparticles were developed 
from a facile, rapid and conveniently-controlled approach.  A triblock polymer was first designed 
and synthesized, based on a novel functional phosphotriester monomer (E4VP), to address the 
safety concern of previous PPE systems on their hydrolytic degradation product, ethylene glycol.  
By a one-pot sequential polymerization of and L-lactide with mPEG as the initiator, the polymer 
was afforded, followed by post-polymerization modification via a thiol-ene click reaction to 
introduce carboxylic acid functionalities.  Solutions of the polymer and silver acetate were 
allowed to mix and stir under UV irradiation to achieve partial reduction of the silver cations.  
Due to the interactions between the polymer and silver species, well-defined Janus nanoparticles 
were formed, as observed by TEM and AFM, with the reaction progress controllable by the 
irradiation time.  Release studies were conducted for these Janus nanoparticles, and ca. 50% of 
silver release was observed within 2 h dialysis against nanopure water. The remaining silver was 
then released in a much slower manner over 40 h, which could be beneficial in treatment of 






5.2 Future Work 
Degradable polymers hold great promise for the development of biomedical materials as 
nanoprobes and nanomedicines, with the advantage to avoid the safety concerns of non-
degradable materials after long-term accumulation in the human body.  Future work will include 
a deeper understanding of rational designs and synthetic strategies of these polymeric systems, 
to achieve optimized performance for the diagnosis and treatment of diseases threatening human 
health and lives.  Moreover, the degradable polymers as well as the synthesis and characterization 
techniques developed in this work should not be limited to the biomedical field, but will also be 
explored for other potential applications, such as antifreeze agents, renewable plastics, etc., to 
address global challenges, including environment pollution and fossil resource depletion.   
For all the nanoprobe and nanomedicines developed in this work, further studies will 
include introduction of target ligands via post-polymerization modification to improve the 
efficacy of diagnosis or treatment and reduce the off-target effects on healthy tissues.  It is also 
desirable to load both imaging and therapeutic agents in the same nanoparticle system for 
theranostic applications.  By introducing cationic charges into the nanostructures, nucleic acids 
could be loaded and delivered for gene therapy.  Rational design of the structures of polymers 
and nanoparticles will be conducted to prepare materials with different responsiveness for better 
selectivity.  Aside from applications in nanotechnology, the functional cyclic phosphotriester or 




hydrogels, by polymerizations followed by crosslinking, which will be investigated for drug 
delivery and tissue engineering.   
Zwitterionic polymers have been reported as advanced materials as antifreeze agents, 
which are capable of preventing or modifying the freezing behavior of water.  Applications of 
these additives include the cryopreservation of blood and tissues, reducing corrosions of steel or 
concrete, and eliminating damage of crops in the agricultural industry.  In Chapter II, the 
degradability and biocompatibility of zwitterionic PPEs have been confirmed as nanoparticle 
coating.  These properties offer the potential of the zwitterionic polyphosphoesters as antifreeze 
agents for both medical and industrial applications, which will eliminate safety concerns and 
pollutions from the additives.  A series of zwitterionic polymers can be afforded from the PPEs 
developed in Chapter II and IV.  Effects of these zwitterionic PPEs on the freezing behavior of 
water will be explored, and the degradability and biocompatibility will be evaluated, to prepare 
antifreeze agents with the optimal antifreeze performance.   
Based on the synthetic strategies and analytical techniques developed in Chapter III, 
sustainable sugar-derived plastics could be obtained from the renewable natural products.  
Investigation and application of these renewable plastics will help address the global challenge 
of depletion of fossil resources.  By investigating the chemical structure and synthetic routes of 
the PGCs, it is expected to develop a library of low-cost sugar-derived polymers with 
degradability and tunable thermal and mechanical properties, which will not only reduce the 
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